Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models. by Anderson, L M et al.
Critical Windows of Exposurefor Children's Health: Cancer in Human
Epidemiological Studies and Neoplasms in Experimental Animal Models
Lucy M. Anderson,1 Bhalchandra A. Diwan,2 Nicola T. Fear,3 and Eve Roman3
1Laboratory of Comparative Carcinogenesis; 21RSP, SAIC Frederick, National Cancer Institute, FCRDC, Frederick, Maryland, USA; 3Leukaemia
Research Fund, Centre for Clinical Epidemiology, University of Leeds, Leeds, United Kingdom
In humans, cancer may be caused by genetics and environmental exposures; however, in the
majority of instances the identification of the critical time window of exposure is problematic. The
evidence for exposures occurring during the preconceptional period that have an association with
childhood or adulthood cancers is equivocal. Agents definitely related to cancer in children, and
adulthood if exposure occurs in utero, include: maternal exposure to ionizing radiation during
pregnancy and childhood leukemia and certain other cancers, and maternal use of diethylstilbestrol
during pregnancy and clear-cell adenocarcinoma of the vagina of their daughters. The list of
environmental exposures that occur during the perinatal/postnatal period with potential to increase
the risk of cancer is lengthening, but evidence available to date is inconsistent and inconclusive. In
animal models, preconceptional carcinogenesis has been demonstrated for a variety of types of
radiation and chemicals, with demonstrated sensitivity for all stages from fetal gonocytes to
postmeiotic germ cells. Transplacental and neonatal carcinogenesis show marked ontogenetic
stage specificity in some cases. Mechanistic factors include the number of cells at risk, the rate of
cell division, the development of differentiated characteristics including the ability to activate and
detoxify carcinogens, the presence of stem cells, and possibly others. Usefulness for human risk
estimation would be strengthened by the study of these factors in more than one species, and by a
focus on specific human risk issues. Key words: cancer, chemical carcinogens, childhood,
exposure, fetus, in utero, ionizing radiation, neonatal, postnatal, preconception. - Environ Health
Perspect 108(suppl 3):573-594 (2000).
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Cancer (as well as other human diseases) may
be caused by genetic and environmental fac-
tors, the relative contribution ofeach to dis-
ease etiology varying from one malignancy to
another. In developed countries, cancer is
principally a disease ofthe elderly, with the
overall incidence rising steadily with increas-
ing age (1). Cancer in children younger than
15 years ofage is rare, accounting for < 1% of
malignancies diagnosed each year in devel-
oped countries (1,2). Furthermore, although
there is some degree ofoverlap, the types of
cancer that occur in youngpeople tend to dif-
fer histopathologically, biologically, and clini-
callyfrom those that occur at older ages (3).
The majority of cancers diagnosed in
children and adolescents are aggressively inva-
sive and grow rapidly. Typically, they are
more receptive to chemotherapy than those
that occur at older ages, and the last 20 years
have seen significant increases in survival over
a wide range ofdiagnostic groups (1,3-5).
Unfortunately, these marked improvements
in cancer treatment have not been matched
by similar insights into cancer etiology, and
the cause or causes ofthe majority ofmalig-
nancies in children and young adults remain
unknown (2,3,6). In fact, with few excep-
tions, there is little evidence to link the
majority ofchildhood and adolescent cancers
with the well-known carcinogens implicated
in adult-onset disease. That having been said,
exposures in childhood are recognized
determinants ofcertain cancers; for example,
early childhood exposure to hepatitis B virus
(HBV) is critical for the development of
hepatocellular carcinoma (7,8) and there is
much circumstantial evidence to support the
suggestion that exposure to infectious agents
in the first few years of life could be an
important risk factor for the development of
acute lymphoblastic leukemia (9).
Exposures in utero have long been thought
to be important determinants ofcertain can-
cers occurring in children and young adults
and in recent years attention has focused on
the possible etiological roles ofa variety offac-
tors acting at this critical time in human devel-
opment. Epidemiological evidence that
prenatal exposures are involved in the develop-
ment ofchildhood malignancy was first pro-
vided by the Oxford Survey of Childhood
Cancers over 40 years ago when an association
between diagnostic radiography of mothers
during pregnancy was related to the subse-
quentdevelopment ofleukemia and other can-
cers in their children (10,11). Although this
association was initially greeted with skepti-
cism, it is nowgenerallyaccepted that the fetus
and young child may be more susceptible to
the effects ofionizing radiation than the adult,
with recent concern revolving mainly around
the importance ofdose and gestational age at
the time ofexposure (12,13). Interest in the
potential carcinogenic effects of in utero expo-
sures was rekindled in 1971 when Herbst et al.
(14) reported an association between the devel-
opment ofclear-cell adenocarcinoma ofthe
vagina in youngwomen and their mothers' use
ofdiethylstilbestrol (DES) during pregnancy.
Recently, although no candidate exposures
were identified, Ford et al. (15) provided mole-
cular evidence that rearrangements at the
genetic locus 11q23, seen in the majority of
infant leukemias, could originate in utero and,
in a further report, they suggested that T-lin-
eage malignancies in older children could also
be initiated in utero(16).
Animal studies have confirmed that a vari-
ety oftypes ofradiation and chemical carcino-
gens given either preconceptionally, in utero,
or directly to the neonate can result in an
increased incidence of neoplasms in the off-
spring (17,18). However, there is a clear lack
ofcomparable human data on this topic. At
present, the only generally accepted carcino-
genic in utero exposures in humans are to ion-
izing radiation and DES, and the suggestion
that parental preconceptional exposures could
potentially influence the risk ofcancer in their
offspring is controversial. Nonetheless, the list
of in utero and preconceptional factors sug-
gested as possible risk factors for human cancer
is ever-lengthening: the most frequently dis-
cussed agents are low-dose ionizing radiation,
hormones (endogenous and exogenous), infec-
tions (specific and nonspecific), and a variety
ofchemicals and drugs (9,19-24.
This review considers the evidence that crit-
ical windows ofexposure exist for human can-
cers and presents the relevant data from animal
models, alongwith adiscussion ofmechanisms.
We also discuss the knowledge gaps in both the
human and animal data and consider some of
the options for future research.
Humans
Exposure Periods
Figure 1 presents a simplified schematic
framework for considering cancer etiology in
relation to the timing of exposure with an
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Figure 1. Schematic framework forconsidering cancer etiology.
example ofeach pathway. In humans, identi-
fiable familial hereditary cancer syndromes
are rare, probably accounting for < 1% of
cancers overall (28,29). For other malignan-
cies, the investigation ofcritical time win-
dows of exposure could span back to the
conception ofan individual's parents (Figure
1). The parental in utero time period may be
more relevant for mothers than for fathers
because oocytes begin their maturation dur-
ing gestation and no new ones are formed
after birth. By contrast, in terms ofprecon-
ceptional transmission, exposures occurring
during an individual's father's life may be
more important than exposures occurring
during their mother's life. This is because
spermatogenesis continues from puberty to
old age and hence there is more opportunity
for preconceptional mutant gene accumula-
tion in men than women (30).
Transgenerational/Preconceptional/
Periconceptional Exposure
Animal experiments have shown that the
exposure of germ cells to carcinogens and
mutagens leads to an excess oftumors in off-
spring (17,31). Despite substantive animal
evidence, there are presently no generally
accepted direct links between the two in
humans. However, there are certain nonfa-
milial recognizable genetic conditions (the
etiologies ofmany ofwhich are unclear) that
predispose toward certain cancers. Although
some are clear defects (e.g., trisomy 21), oth-
ers are not (e.g., ethnicity and sex). The effect
ofsex deserves particular attention because in
most populations males are significantly more
likely to be diagnosed with cancer than
females. Further, sex selection occurs in cer-
tain animal species (3Z) and there is epidemi-
ological evidence that environmental risk
factors may alter the probability ofhaving a
child ofone sex or the other. The most fre-
quently suggested exposures relate to paternal
occupation (33-37).
The association between childhood cancer
and sex is illustrated in Tables 1 and 2, where
national data are presented for England and
Wales for 1981-1990 and for the U.S.
Surveillance, Epidemiology, and End Results
cancer registry for 1983-1992 (38). In
human communities, male births generally
account for 51-53% ofall births, yielding a
sex ratio ofapproximately 1.05. During the
first year oflife, although the majority ofcan-
cers are just as likely to be diagnosed in girls
as in boys, a characteristic male predomi-
nance begins to emerge with increasing age
(Tables 1 and 2). These sex differences are
particularly noticeable for the more common
forms ofchildhood cancer: the overall male-
to-female ratio for leukemia and tumors of
the central nervous system, each ofwhich
account for around one-fifth ofall childhood
cancers, is approximately 1.2. However, the
largest differences are seen for the lymphomas
(Hodgkin and non-Hodgkin), where males
are approximately twice as likely to contract
the disease.
AsociationswithInheritedGenetic
Disorders
Recognized genetic syndromes and familial
aggregation account for a relatively small pro-
portion of total cancers-probably no more
than 5%. This proportion varies with cancer
type and age at diagnosis.
Retinoblastoma. Retinoblastoma, which
is a rare cancer accounting for approximately
2% ofall malignancies diagnosed in children
younger than 15, has become a paradigm for
considering the etiological role ofgenetic fac-
tors in cancer epidemiology. In 1971,
Knudson (39) proposed a two-mutation
hypothesis to explain the occurrence of
retinoblastoma in both hereditary and spo-
radic forms with differing frequencies of
bilaterality. Knudson suggested that in hered-
itary cases the first mutation occurred in a
germinal cell and the second in a somatic cell,
whereas in nonhereditary cases both muta-
tions occurred postzygotically in the same
somatic cell line. Hereditary cases were fur-
ther subdivided into familial (accounting for
approximately one-quarter ofall hereditary
cases and one-eighth ofall cases) and nonfa-
milial (accounting for approximately three-
quarters of all hereditary cases and
three-eighths ofall cases). Knudson's model
has since been confirmed using molecular
techniques, with heritable cases characterized
by a constitutional 13q deletion (40,41).
With respect to etiology, the origins of
nonfamilial retinoblastoma are unclear. The
majority ofnew germline mutations (sporadic
heritable) appear to be paternally derived, but
no consistent associations with paternal expo-
sures have yet been demonstrated (42-44). In
Table 1. Number of cases (%) and sex ratios (male/female) by age for England and Wales, 1981-1990.
Cancer
Leukemia
Lymphoid
Lymphomas
Hodgkin disease
Non-Hodgkin
Brain and spinal
Ependymoma
Astrocytoma
SNS tumors
Retinoblastoma
Renal tumors
Hepatic tumors
Bone tumors
Osteosarcoma
Soft-tissue sarcoma
Germ cell and gonadal
Carcinomas
Total
SNS, sympathetic nervous system
Total (%)
3,705 (33)
2,959(26)
1,134(10)
489 (4)
559 (5)
2,549 (23)
275 (2)
977 (9)
797 (7)
312(3)
654 (6)
101 (1)
546(5)
284(3)
776 (7)
397 (4)
341 (3)
1,352 (100)
0
0.8
0.7
0.5
0.3
1.0
1.5
0.8
1.0
1.4
1.1
1.1
1.3
2.0
1.1
1-4
1.2
1.2
1.9
2.8
1.6
1.3
1.3
1.2
1.1
1.0
0.9
2.5
0.8
1.5
1.3
1.3
0.8
1.2
Age (years)
5-9
1.2
1.3
3.5
3.4
3.9
1.2
1.8
1.0
1.3
1.3
0.8
0.7
0.8
0.6
1.1
0.6
1.0
1.3
10-14
1.4
1.6
2.1
1.9
2.4
1.3
1.1
1.2
1.3
1.1
1.7
1.0
1.0
1.1
0.6
0.8
1.3
0-14
1.2
1.3
2.4
2.2
2.5
1.2
1.4
1.1
1.1
1.2
0.9
1.4
0.9
0.9
1.2
0.9
0.8
1.2
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the same study, Bunin et al. (42) reported an
association between sporadic heritable
retinoblastoma and self-reported maternal
X rayofthe lower abdomen or pelvis.
Wilms' tumor. Wilms' tumor is an
embryonal tumor, accounting for approxi-
mately 90% ofall kidney cancers diagnosed in
children younger than 15 years ofage (45,46).
It is the fourth most common childhood
cancer, accounting for approximately 6% of
all cancers diagnosed before 15 years ofage
(46), and it occurs with equal frequency in
boys and girls (Tables 1 and 2). Wilms' tumor
is extremely rare in those over the age of 15,
although it has been seen in adults (47).
Familial Wilms' tumor accounts for < 1%
ofWilms' tumor cases; approximately 20% of
familial cases are bilateral compared to 3% of
sporadic cases (48). Because of similarities
between Wilms' tumor and retinoblastoma,
Knudson and Strong (49) initially proposed a
similar two-hit mutational model to explain
its occurrence in both hereditary and sporadic
forms with differing frequencies ofbilateral-
ity. Subsequent studies revealed, however,
that the pathogenesis ofWilms' tumor was
far more complex. Further work led to the
identification and cloning of the Wilms'
tumor-suppressor gene (VWTi) located at
chromosome l 1pl3 (50). A second suppres-
sor gene has been suggested (WT2); this gene
is located on chromosome 11p15 (51).
Associations with certain congenital anom-
alies have been described, including WAGR
syndrome (Wilms' tumor with congenital
aniridia, genitourinary abnormalities, and
mental retardation), Beckwith-Wiedemann
syndrome, Perlman syndrome, Denys-Drash
syndrome, and hemihypertrophy (52).
As with retinoblastoma, de novo Wilms'
tumors appear to be largely paternally derived
(53). Inherited mutations of WTi have been chromosome breakpoint 11pl5 (Beckwith-
demonstrated in cases ofWilms' tumor; in Wiedemann syndrome) and Wilms'
some instances the mutation came from the tumor (52.
father, whereas in other cases the mutation * Chromosomal instability syndrome: frag-
arose during paternal gametogenesis (54,55). ile chromosome site at 9q22 (Fanconi
Genomic imprinting has been proposed as anemia) and acute myeloid leukemia (78).
another mechanism involved in the pathogen- With respect to the origin and timing of
esis ofWilms' tumor. Genomic imprinting is potentially hazardous exposures (Figure 1),
defined as a "gamete specific modification ofa aneuploidy predominately arises from mater-
gene resulting in differential expression in nal errors of segregation at the first meiosis
somatic cells" (56). Genomic imprinting ofa (79,80), whereas point mutations and chro-
transforming gene on the maternally derived mosomal rearrangements tend to result more
chromosome 11 has been suggested as an alter- commonly from paternal errors (79). The ori-
native explanation for preferential maternal gin of chromosomal instability syndromes
allele loss. is unclear.
With respect to etiology, several studies Associations with specific exposures. The
have demonstrated an association between suggestion that preconceptional exposures of
childhood Wilms' tumor and father's occupa- parents' germ cells could influence cancer risk
tional exposure to pesticides or employment in their offspring is controversial. Although
in the agricultural industry (36,57-59). there is more literature emerging on the
Other cancers andgenetic disorders. potential effects of parental lifestyle factors
Associations with specific congenital anom- such as smoking, diet, and alcohol consump-
alies have been described for a number of tion (81-83), the main areas of interest to
cancers other than Wilms' tumor. Examples date have been in the children ofindividuals
of the four types ofgenetic disorders and the given chemotherapy and those exposed to
cancers with which they have been associated unusual levels of ionizing radiation. With
are given below: respect to chemotherapy, the marked
* Aneuploidy: a) trisomy 21 (Down syn- improvements in survival among children
drome) and acute leukemia (60-70). [The and young adults treated for cancer have
relative risk ofdeveloping acute leukemia given rise to concern about possible germ-cell
among children with Down syndrome is damage, but, at present, the data are sparse
high-approximately 30-fold (6)] and b) (84-86). With respect to ionizing radiation,
monosomy X (Turner syndrome) and particular controversy surrounds the sugges-
neuroblastoma (71). tion that germ-cell damage caused by low
* Point mutations: mutations in the NF-I doses of external ionizing radiation might
gene (neurofibromatosis) and tumors of increase the risk ofcancer and other genetic
the central nervous system (72-74), rhab- diseases in the progeny ofthose exposed. The
domyosarcoma (75), and leukemia findings for paternal occupational exposure,
(72,76,77). which is one of the few areas where good
* Chromosomal rearrangements: duplica- individual dose data are available, are
tion or unbalanced translocation of reviewed below.
Table 2. Numberof cases (%) and sex ratios (male/female) byage for U.S. Surveillance, Epidemiology, and End Results (SEER), 1983-1992.
Cancer
Leukemia
Lymphoid
Lymphomas
Hodgkin
Non-Hodgkin
Brain and spinal
Ependymoma
Astrocytoma
SNS tumors
Retinoblastoma
Renal tumors
Hepatic tumors
Bone tumors
Osteosarcoma
Soft-tissue sarcoma
Germ cell and
gondal
Carcinomas
Total
Total, age (years)
Total (%) 0 1-4 5-9 10-14 0-14 Total(%) 0
2,009(30) 0.8 1.2 1.4 1.3 1.2 1,757(31) 0.8
1,599(24) 0.5 1.2 1.5 1.4 1.3 1,420(25) 0.5
702(11) 1.7 1.9 2.8 1.7 2.0 616(11) 2.5
293(4) - 7.0 2.7 1.1 1.5 259(5) -
260 (4) 1.0 1.4 2.4 2.6 2.2 224(4) 2.0
1,437 (22) 1.0 1.2 1.2 1.2 1.2 1,222(21) 0.9
143(2) 2.0 1.5 1.8 2.0 1.6 117(2) 1.6
726(11) 1.3 1.0 1.1 1.1 1.1 624(11) 1.3
548(8) 1.2 1.2 0.9 0.5 1.2 469(8) 1.2
216(3) 0.9 1.0 1.5 - 1.0 172(3) 0.9
433(6) 1.2 0.9 1.1 1.6 1.0 366(6) 1.2
97(1) 0.7 1.4 5.0 0.4 1.0 83(2) 0.8
306 (5) - 0.5 0.9 1.2 1.1 267(5) -
164(2) - 0.4 1.2 1.0 1.0 136(2) -
470(7) 1.2 1.3 1.3 1.0 1.2 387(7) 1.3
206(3) 0.6 1.8 0.4 0.4 0.6 165(3) 0.6
Whites, age(years)
1-4 5-9 10-14
1.2 1.5 1.2
1.2 1.6 1.3
2.2 2.8 1.7
7.0 2.6 1.1
1.6 2.4 2.7
1.3 1.3 1.2
1.5 2.0 2.2
1.0 1.1 1.1
1.3 0.9 0.4
1.2 1.3 -
0.9 1.1 1.4
1.3 4.0 0.3
0.6 0.9 1.2
0.5 1.3 1.1
1.4 1.4 1.1
1.6 0.6 0.5
Blacks, age(years)
I Total(%) 0 1-4 5-9 10-14 0-14
189(25) 1.0 1.0 1.2 1.6 1.1
133(18) 0.4 1.0 1.0 3.1 1.2
72(10) - 0.5 3.8 1.7 1.7
30(4) - - 4.0 1.2 1.7
31(4) - 0.3 6.0 2.0 1.6
176(23) 2.0 1.0 0.9 1.3 1.0
22(3) - 1.3 1.0 1.0 1.4
87(12) 1.0 0.9 1.0 1.6 1.1
61 (8) 1.1 0.9 - 1.0 0.9
32(4) 1.6 0.6 - - 1.1
59(8) 0.8 0.8 0.7 2.0 0.8
12(2) 0.3 4.0 - 1.0 1.4
27(4) - - 1.0 0.5 0.6
23(3) - - 1.3 0.5 0.6
74(10) 0.6 1.1 1.3 0.9 1.0
32 (4) 0.2 2.0 - 0.2 0.2
220 (3) 2.3 1.0 0.8 0.6 0.7 193(3) 2.3 1.0 0.6 0.5 0.6 20(3) - - 2.5 0.9 1.2
6,669(100) 1.0 1.2 1.3 1.1 1.2 5,718(100) 1.0 1.2 1.4 1.1 1.2 758(100) 0.9 0.9 1.1 1.0 1.0
SEER data from Parkin et al. (38). SNS, sympathetic nervous system.
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Ionizing radiation. The hypothesis that
occupational preconceptional exposure of
fathers to external sources of ionizing radia-
tion increases the risk ofleukemia in their off-
spring derives mainly from the case-control
study conducted by Gardner et al. (87). In
1990, theywrote:
The main finding ofthis study is that the
recorded external dose ofwhole body ion-
ising radiation to fathers during their
employment at Sellafield is associated with
the development ofleukaemia in their chil-
dren.... The results suggest highest risks in
those with highest accumulated ionising
radiation doses before conception, either
over their total duration of exposure or
during the preceding six months.
These statements were based on two results in
their study. Compared to the offspring of
fathers with no record of monitoring for
external sources of ionizing radiation at
Sellafield, those whose fathers had a lifetime
cumulative dose of 100 mSv or more before
their child's conception were estimated as 8.4
[95% confidence interval (CI), 1.4-52.0]
times more likely to develop leukemia. The
four case fathers with a cumulative precon-
ceptional dose of> 100 mSv received 10 mSv
of this dose in the 6 months before their
child's conception, yielding a relative risk of
6.8 (CI, 1.5-31.9) (88).
Results from four other case-control
studies (89-92) and one cohort study
[Nuclear Industry Family Studies (NIFS)
(27)] that examined paternal preconceptional
dosimetry data are compared with those of
Gardner et al. (87,88) in Tables 3 and 4. As
with the West Cumbrian investigation in the
United Kingdom, the studies in Caithness
[which contains the Atomic EnergyAuthority
(AEA) Dounreay plant] (89), West Berkshire
[which contains the Atomic Weapons
Establishment (AWE) plants at Aldermaston
and Burghfield] (91), and five regions in
Ontario containing a nuclear facility (90)
were specifically targeted at leukemia and
non-Hodgkin lymphoma cases in the vicinity
of nuclear plants. The record-linkage study
aimed at national coverage by using birth cer-
tificate identifiers to link U.K. registration
data on all childhood cancers to data on
workers included on the National Registry of
Radiation Workers (92).
Lack ofhuman data is one of the main
messages that comes across from Tables 3 and
4. In addition, the U.K. studies are not inde-
pendent: NIFS (27) and the record-linkage
study (92) have the potential for overlap with
the case-control studies conducted in West
Cumbria (87), Caithness (89), and West
Berkshire (91). For fathers monitored for
radiation exposure and for those exposed to
. 100 mSv before their child's conception,
the effect of this overlap is small for all but
the West Cumbrian study. More impor-
tantly, perhaps, the NIFS and the record-
linkage studies have the potential for overlap
with each other: approximately halfof those
Table3.Summaryofstudiesthathaveexaminedtheriskofcanceramongchildrenwhosefatherswere monitored foroccupational exposureto ionizing radiation beforethechild'sconception.
U.K., U.K., U.K., Canada, U.K. (record-linkage study)a U.K. (NIFS)b
West Cumbriac Caithnessd West Berkshiree Ontariof All data All data9 All data All data9
Studydescription
Design Case-control Case-control Case-control Case-control Case-control Case-control Cohort Cohort
Age range(years) 0-24 0-24 0-4 0-14 0-14 0-14 0-24 0-24
Years ofdiagnosis 1950-1985 1970-1986 1972-1989 1950-1988 1952-1986 1952-1986 1951-1993 1951-1993
All malignancies
Monitored ND ND ND ND 1.3(0.9-1.9) 1.3 (0.9-1.9) 1.4(0.9-2.2) 1.5(0.9-2.5)
2 100 mSv ND ND ND ND 1.2 (0.3-4.3) 0.7 (0.1-3.4) 2.2 (0.9-5.3) 4.1 (1.4-11.8)
Leukemia and NHL
Monitored 1.1 (0.5-2.7) NR 9.0 (1.0-108.8) ND 1.8(1.1-3.0) 1.8 (1.1-3.0) 1.8(0.7-4.4) 2.2(0.7-6.6)
2 100 mSv 8.6(1.4-52.2) 0.0 ND ND 1.4(0.3-7.2) 0.5 (0.0-5.2) 3.9(1.0-15.7) 4.3(0.5-40.5)
Leukemia
Monitored 1.4(0.5-3.9) NR NR 1.0 (0.5-2.2) NR NR 2.2(0.8-6.1) 2.9(0.8-10.3)
> 100 mSv 8.4(1.4-52.0) NR ND 0.0 NR NR 5.8(1.3-24.8) 6.6(0.7-67.1)
All malignanciesh
Monitored ND ND ND ND 0.9 (0.6-1.6) 0.9(0.6-1.6) 1.3(0.7-2.2) 1.3 (0.7-2.3)
2 100 mSv ND ND ND ND 1.0 (0.1-13.8) 1.0(0.1-13.8) 1.5(0.5-5.0) 4.0(1.2-13.6)
Forexplanation ofstudydata, see Table 4. Abbreviations: ND, nodata; NHL, non-Hodgkin lymphoma; NR, not reported.
"Data from Draper et al. (92). bData from Roman et al. (27) and Maconochie et al. (93). cThe Gardner et al. study (87,88). dData from Urquhart et al. (89). "Data from Roman et al. (91). fData from
McLaughlin etal. l90). 9Withoutthe Gardner et al. study(87,88). hExcept leukemia and NHL.
Table 4. Explanation of study data for those studies that have examined the risk of cancer among children whose fathers were monitored for occupational exposure to ionizing
radiation beforethe child's conception.
Total casesa Total controlsa
Reference Cancertype Monitored > 100 mSv Total Monitored > 100 mSv Total
Gardner etal. (1990, 1992)(87,88 Leukemia and NHL 10 4 66 58 3 389
Leukemia 8 4 46 40 3 276
Urquhart etal. (1991)(89 Leukemia and NHL NR 0 12 NR 1 45
Roman et al. (1993)(91) Leukemia and NHL 3 0 54 2 0 324
McLaughlin etal. (1993)(90) Leukemia 10 0 112 81 5 894
Draper etal. (1997)(92) All malignancies 82(73) 6(3) 34,538(34,510) 79(73) 7(6) 36,912 (36,884)
Leukemia and NHL 49(40) 4(1) 13,649 (13,621) 44)38) 5)4) 16,023115,995)
All malignancies 33(33) 2)2) 20,889)20,889) 35(35) 2 (2) 20,889 (20,889)
except leukemia and NHL
Roman et al. (1999)127) All malignancies 39(29) 6 (4) 94(74) NA NA NA
Leukemia and NHL 14(10) 3 (1) 28(20) NA NA NA
All malignancies
except leukemia and NHL 25(19) 3 (3) 66(54) NA NA NA
Abbreviations: NA, notapplicable; NHL, non-Hodgkin lymphoma; NR, not reported.
&Numbers in parentheses are totals minusthe cases and controls, respectively, from the Gardner et al. study(87,88).
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listed on the National Registry for Radiation
Workers that were defined as eligible for the
record-linkage study were employed at one
time by the AWE, AEA, or British Nuclear
Fuels Limited (92). Indeed, the relative risk
estimates for leukemia and non-Hodgkin
lymphoma in offspring, in relation to pater-
nal monitoring for exposure to ionizing radia-
tion before their child's conception, are
virtually the same in NIFS and the record-
linkage study: both studies estimated that the
children of monitored workers had an
approximate 80% increased risk compared to
the children of nonmonitored workers.
Despite this similarity, there is little evidence
in the record-linkage study ofany increased
risk in the 100-mSv dose categories. Indeed,
in the record-linkage study, the significantly
raised risk of 1.8 (CI, 1.1-3.0) for leukemia
and non-Hodgkin lymphoma among chil-
dren ofmonitored fathers has its origins in an
8-fold elevation in risk (CI, 1.2-4, based on
six cases) among those with dose levels below
detection (92). Such low doses were rare in
NIFS: only 2% of liveborn children were
conceived by a father who had a cumulative
whole-body dose of< 0.1 mSv (93).
Data ofthe type shown in Tables 3 and 4
are sparse and cannot be broken down into
nonoverlapping exposure periods. In all of
the studies, fathers exposed to high doses of
external ionizing radiation immediately
before conception were also more likely to be
exposed to high doses before that time.
Similarly, fathers exposed before their child
was conceived were often exposed throughout
their child's life. In addition to being unable
to isolate relevant time windows ofexposure,
the nature of the hazardous exposure if it
exists behind the associations depicted in
Tables 3 and 4 remains unknown.
In UteroExposure
Unlike the situation for preconceptional expo-
sures, there is good evidence that exposure of
the human fetus to certain potentially harmful
agents can increase the risk of cancer during
childhood and possibly during early adult-
hood (11,14-16,67,68,94-96). Nonetheless,
although numerous potentially harmful agents
are suspected including infections, drugs,
and maternal lifestyle characteristics [reviewed
by Little (6)] the only two generally
accepted carcinogenic in utero exposures are
ionizing radiation and DES: the former acting
directly on the fetus and the latter acting via
the placenta (Figure 1).
The strong associations for DES have led
researchers to postulate in utero effects for
other endogenous and exogenous hormones,
particularly for cancers with a suspected hor-
monal component to their etiology such as
breast and testicular cancers (97-101).
Further, since the birth of the first test-tube
baby in 1978 there has been concern about the
health of offspring resulting from assisted
reproductive technology (ART). Multiple
pregnancies often result from ART, which is
one ofthe main determinants ofthe health of
the child at birth (102-104). The importance
offollow-up studies ofthese children to assess
adverse health outcomes diagnosed after birth,
even in adulthood, has been recognized, but
few comprehensive and powerful epidemiolog-
ical studies have been done. Two case reports
have highlighted possible increases in cancer
incidence in children born as a result of in
vitro fertilization (105,106), raising concerns
about the role ofprenatal exposure (before and
after conception) to high levels ofestrogen and
related compounds used for ovarian stimula-
tion. To date, there are limited epidemiologi-
cal data on this topic; a study of U.K. births
after ART failed to find an excess incidence of
childhood cancer (24), but, as noted by the
authors, the study was too small to be able to
detect a reasonable excess, even ifit existed.
With respect to mechanisms and the
timing ofexposure, it is thought that the car-
cinogenic effects of both ionizing radiation
and DES may be mediated via teratogenesis
(107,108). This has been documented for
DES, which causes various genital tract
abnormalities in males as well as in females
Table 5. Estimated relative risks for the association between neonatal administration of IM vitamin K and childhood
cancer.
All leukemias
Reference Country Study design HR Cl Age range
Golding et al. (111) England Case-control 2.65 1.34-5.24 0-14 years
Ekelund et al.(11 Sweden Case-control 0.90 0.70-1.16 1 month-18 years
Klebanoff et al. (113) United States Case-control 0.47 0.14-1.55 0-7 years
Olsen et al. (114) Denmark Cohort 1.00 0.93-1.09 1-13 years
Ansell et al. (115) England Case-control 1.30 0.70-2.30 0-14 years
von Kries et al. (116) Germany Case-control 0.98 0.64-1.50 1 month-14 years
McKinney et al. (117) Scotland Case-control 1.30 0.83-2.03 0-14 years
Parker et al. (118) England Case-control 1.20 0.75-1 .92a 3 months-14 years
Parker et al. (118) England Ecological 0.95 0.78-1 .17a 3 months-14 years
Passmore et al. (119) England and Wales Case-control 1.53 0.82-2.85 1-14 years
Passmore et al. (119) England and Wales Ecological 1.13 Not quoted 1-14 years
RR. relative risk
aAcute lymphoblastic leukemia only.
(107,109). In addition, it has been suggested
that the exposure ofpregnant women to sub-
stances that inhibit the function ofthe topoi-
somerase II enzymes could be related to the
development of acute leukemia in their
offspring (9).
Perinatal/Postnatal Exposures
The list of environmental exposures that
increase cancer risk is exceedingly long and, for
the most part, outside the scope ofthis review.
We discuss only those agents where childhood
exposure is either known, or suspected, to be
critical to cancer development.
Vitamin K. The efficacy ofintramuscular
(IM) vitamin K prophylaxis in preventing
both hemorrhagic diseases in neonates and
late-onset bleeding disorders in breast-fed
babies is well established (110). The prophy-
lactic administration ofvitamin K to neonates
became a controversial topic when Golding
et al. (111) reported in 1992 that children
who received it by the IM route were almost
3 times more likely to develop leukemia than
children who received it orally or not at all.
Although subsequent studies failed to con-
firm these findings (95,112-119), inconsis-
tencies in their results left lingering doubts
about the safety of administering parenteral
vitamin K (120). The main results of the
studies conducted to date are presented in
Table 5. After neonatal administration ofIM
vitamin K, the risk estimates ranged from
0.47 to 2.65 for all childhood leukemias. The
largest risk estimate arose from the relatively
small, hypothesis-generating study conducted
in Bristol, United Kingdom (111).
Infections. Specific infectious/parasitic
agents are now recognized as major causes of
certain cancers, including various types of
papilloma viruses in cervical cancer; hepatitis
B and C in hepatocellular carcinoma;
HTLV-1 in T-cell leukemia/lymphoma;
Epstein-Barr virus in Burkitt lymphoma;
Helicobacterpylori in gastric cancer; HHV-8
in Kaposi sarcoma; and Schistosoma haemato-
bium in bladder cancer [reviewed by Newton
et al. (121)]. Overall, approximately 15% of
all human malignancies can be attributed to
viral, bacterial, or helminth infections.
Age at first exposure when chronic or
persistent infection begins is critical for the
development of many of these malignancies.
For example, children infected with HBV
perinatally by their mothers have an
85-100% chance ofbecoming chronic carri-
ers, compared to a 20-30% chance ifthey are
infected between the ages of 1 week and 5
years. Although HBV persistence is a major
risk factor for hepatocellular carcinoma
(accounting for > 50% of the disease), the
mechanisms by which persistence is estab-
lished and hepatocellular carcinoma ensues is
still the subject of much current research (8).
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In contrast to viruses such as HBV, many of
which are directly oncogenic, many bacteria
and helminthes act indirectly by causing tis-
sue damage. Nonetheless, as with HBV, the
establishment ofa persistent infection in
childhood has been suggested to be associated
with the largest increase in disease risk: child-
hood exposure to Helicobacterpylori, for
example, is thought to be more important for
gastric cancer development than exposure at
older ages (122.
In addition to the dassic associations with
persistent infections, there is considerable
speculation about the role that infectious
agents may play in the etiology ofleukemia
[reviewed by Little (6), Greaves (9), and
Kinlen (23)]. The two main hypotheses,
which have become known as the Greaves
and Kinlen hypotheses, are as follows:
* Greaves (9) hypothesized that many
childhood leukemias, particularly com-
mon acute lymphoblastic leukemia
(c-ALL) diagnosed in the childhood peak
(2-5 years ofage), arise as a consequence
ofa rare abnormal response to a common
infection (Figure 2). Greaves stated that
the infection may be oflow pathogenicity
and unusual in its timing and that genetic
factors or susceptibility may influence the
abnormal response leading to leukemia.
* Kinlen (23) proposed that leukemia (and
possibly non-Hodgkin lymphoma) in
children and young adults may be caused
by a specific viral infection, the transmis-
sion ofwhich is promoted by population-
mixing. Drawing on animal models, he
suggested that epidemics ofthe specific
causative infection (and hence epidemics
ofleukemia) occur rarely and mostly in
rural populations.
Although there is alarge bodyofepidemi-
ological data accruing on this topic, which is
the subject of much current research, no
viruses or definitive immunological mecha-
nisms haveyet been identified.
Other childhood exposures. Clearly,
a number ofother childhood exposures-
aside from infections and immunological
processes-are likely to influence adult health.
The question for this review is whether the
consequences ofchildhood exposure differ
from the consequences of adult exposure.
There is some suggestion that children may be
more susceptible than adults to comparable
doses ofionizing radiation and chemotherapy
(108,123-125). Similarly, Truhan (126) sug-
gested that exposure to excessive amounts of
ultraviolet light in childhood may be the main
cause ofmelanoma in adulthood.
The potential etiological role ofdiet in
childhood also deserves particular mention.
The influence of breastfeeding-which is
clearly related to early life-is the subject of
much current research. In this context it
should be remembered that aswell as the pro-
tective immunological effects postulated for
conditions such as leukemia, deleterious
effects-involving the transmission ofagents
such as HBV, human immunodeficiency
virus, and fat-soluble chemicals-are also
possible. Further, in these latter cases mater-
nal exposure may have occurred several years
before the index pregnancy (Figure 1).
Animal Models
Preconceptional/Transgenerationai
Effects
Transgenerational carcinogenesis, wherein the
exposure ofa parent before mating results in
increased tumors in offspring and sometimes
in subsequent generations, has been demon-
strated for several types ofradiation and a vari-
ety ofchemical carcinogens [(17,127,128),
Tables 6 and 7]. The tumors affected tend to
be those that have a spontaneous incidence in
the species and strain (lung, liver, or lymphoid
system ofmice) or are relatively easy to induce
(skin and reproductivesystem in mice and ner-
vous system in rats). Results for male-mediated
transgenerational carcinogenesis are summa-
rized in Table 6. Exposures ofall possible
stages of sperm development have given
positive results-stem cells through mature
sperm in the adult, and the embryonic
gonocytes ofgestation day (GD) 9 ofmice and
fetal testicular germ cells later in gestation in
mice and hamsters.
The weight of the evidence leaves little
doubt that exposures ofmales can in fact lead
to increased incidence of neoplasia in off-
spring. However, attempts to reproduce key
findings have sometimes been partially or
completely unsuccessful, indicating that the
phenomenon is highly influenced bygenetics,
husbandry conditions, or other unknown
variables. Thus, preconceptional carcinogene-
sis for the nervous system in rats by ethyl-
nitrosourea (ENU) (129) could not be
demonstrated with statistical significance in a
later study (130). Preconceptional exposure
to X rays ofICR or SHR (Swiss) mice led to
increased lung tumors or increased suscepti-
bility to postnatal induction ofthese tumors
in offspring (131-133), but this effect could
not be reproduced in BALB/c (134) or C3H
(135) mice and only minimal effects were
seen in CBA mice (136). X-irradiation ofthe
spermatogonia of N5 mice resulted in
increased incidence ofleukemia in offspring
(137); mice ofthis same strain were treated
withX rays or tritium at the postmeiotic stage
several decades later in another laboratory,
and the treatment had a borderline effect on
leukemia incidence (138).
Similarly, urethane had pronounced
preconceptional carcinogenic effects on
lung tumor incidence in ICR Swiss mice
(131,132,139), but treatment ofNational
Institutes ofHealth (NIH) Swiss male mice
at the spermatid stage with this carcinogen
had minimal effects on lung tumor incidence
in offspring (140), and no significant effects
in CBA mice (136). However, in the NIH
Swiss mouse study, after paternal urethane
treatment there were significant increases in
incidences ofpheochromocytomas in both
sexes, lymphoma in females, and neoplasia of
the forestomach in males (140); in CD-1
Swiss mice, urethane exposure offathers led
to significant increases in tumors ofthe liver
in male offspring (141). To explain this wide
variety ofeffects, the molecular mechanism of
preconceptional carcinogenesis must be
understood. When this is accomplished, more
light may be shed on the likelihood ofthe
phenomenon occurring in humans.
Only a few models have been investigated
in sufficient detail to permit comparisons of
the relative sensitivity ofvarious stages oftes-
ticular development and spermatogenesis. In
adult ICRmice, X-ray and urethane exposure
appeared to have the greatest effect at the
postmeiotic spermatid stage; spermatogonia
were affected by X ray but not urethane
(131). For ICR and LT mice, the effects in
causing leukemia by paternal X-ray exposures
were greatest for postmeiotic treatment, but
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Figure 2. An immunological model for the etiology of
childhood common acute lymphoblastic leukemia
(c-ALL). Adapted from Greaves(9.
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Table 6. Preconceptional carcinogenesis in animals: male exposure followed by mating with an untreated female.
Germ cell stage at
Species/strain exposurea Exposure agent/doseb Site of neoplasmsc Reference
1-7 days to
64-80 days;
gonia-sperm
GD 9; migrating/
dividing
gonocytes
GD 15; dividing
gonocytes in genital
ridge oftestis
1-20 days; postmeiotic
Postmeiotic
Gonia
3-14 days, late
spermatid/sperm
1-7 days, late
spermatids, sperm
1-7 days, late
spermatids, sperm
> 50 days, stem cells
0-7 days, sperm
7-14 days, spermatids
0-7 days, sperm
7-14 days, spermatids
7, 21, 63 days; sperm,
late meiosis, gonia
3-14 days, late
spermatid/sperm
14 days, spermatids
90 days, gonia
15 days, postmeiotic
late fetal; gonia
GD 17; nondividing
oocytes
GD 17; nondividing
oocytes
8-14 days; late,
spermatids, sperm
29-35 days; gonia,
early meiosis
36-42 or 50-56 days;
gonia
64-80 days; stem cells
7,61,63 days
7 days; sperm
14 days, spermatids
Fetal day 12
Fetal day 13
Fetal day 14
Fetal day 15
2 weeks, spermatid
7 days (sperm), 21 days,
(spermatocytes) or
28 days (spermatogonia)
1,14, 21,or28days
Continuous for 30 days
(spermatocytes,
spermatids, sperm)
14 days, spermatids
Fathers 3 or
25 months old
X ray, 216 rad Lung; significant effects on incidence for 8-14, 15-21, and 64-80 days; (131)
on multiplicity for 8-14 days
X ray, 216 rad Lung, after postnatal urethane (133)
{No increase in lung tumors}
X ray, 504 rad
X ray, 500 cGy
X ray, 4.2 Gy
X ray, 4.2 Gy
X ray, 600 R
X ray, 250 or 509 cGy
X ray, 250 or 509 cGy
X ray, 1 or 2 Gy
Tritium, 100 or 150 cGy
252Cf (67% neutrons,
33% y-rays), 50, 100 cGy
Coy, 3 Gy
DMBA, 400 pg/mouse
Diethylstilbestrol,
1 mg/kg
Urethane,
1.5 g/kg
Urethane, 1.5 g/kg
Urethane, 1 g/kg
Urethane, 1.75 mg/kg
Urethane, 1.5 g/kg
NDEA, 10 mg/kg
NDEA, 10 m/kg
ENU, 80 mg/kg
ENU, 80 mg/kg
Cyclophosphamide,
3.5-5.2 mg/kg
daily
Chromium chloride,
1 mmol/kg
No treatment; age as
variable
Lung, after postnatal urethane
Lung, leukemia
lung, leukemia
leukemia (p= 0.09)
Lung (increased sensitivity to postnatal urethane)
Mammary (decreased latency)
Skin (TPA-promoted tumors)
[Lung, females, decreased]
{Lung tumors, no effects}
{Lung tumors, no effects}
{Lung tumors, no effects, no increase in sensitivity to urethane}
{Lung tumors, no effects, no increase in sensitivity to urethane}
7 days, [decrease in lung tumors in females]; nonsignificant increase in
hematopoietic tumors in females and lung adenocarcinomas in males
Leukemia, reduced latency, significanttrend with days before mating
Liver
Liver(smaller effect than with 14-daytreatment)
Liver, p= 0.06
[Decreased histiocytic sarcomas, females]
{No effect}
Uterus (sarcoma); lymphoma; ovary (granulosa-thecal cell and tubular adenoma);
{No changes in male offspring}
{No increase in lung tumors}
Lung
Lung
Lung
{No effect on lung tumors}
{No increase in lung, or liver tumors}; nonsignificant increase in
hematopoietic tumors in females
Liver(male offspring only)
Adrenal pheochromocytoma; preneoplasia/neoplasia of glandular
stomach; lymphoma (females); [decrease in histiocytic sarcoma]
{No effect}
Larynx/trachea, neuroendocrine tumors, increased ratio malignant/benign,
increased multiple tumors; increased uterine tumors, lymphoma
Larynx/trachea, neuroendocrine tumors, increased ratio malignant/benign,
increased multiple tumors; increased uterine tumors, lymphoma
{No effect}
Nervous system
Nervous system, nonsignificant increases
{Nervous system, no effect}
[Thyroid, not significant after litter effect correction]
Uterus (not all tumors diagnosed)
Adrenal pheochromocytoma; lung (females); thyroid; Harderian gland
Offspring treated with methyinitrosourea, 20 mg/kg, at 3 months: shorter
survival oftumor-bearing offspring of older fathers
(13?
(138)
(211)
(212X
(213)
(134)
(135
(136)
(13?
(143,144)
(214)
(215)
(216)
(139)
(131)
(136)
(141)
(140)
(145
(21?
(129)
(130)
(218)
(140)
(219)
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Mouse/ICR
Mouse/ICR
Mouse/LT
Mouse/N5
Mouse/N5
Mouse/SHR
Mouse/SHR
Mouse/C3Hf
Mouse/BALB/c
Mouse/C3H/HeH
Mouse/CBA
Mouse/N5
Mouse/C3H x
C57BL/6
Mouse/C57
Mouse/MA
Mouse/CBA
Mouse/ICR
Mouse/ICR
Mouse/CBA
Mouse/CD-1
Mouse/NIH Swiss
Hamster/SG
Hamster/SG
Rat/BDVI
Rat/BDVI
Rat/SD
Mouse/NIH Swiss
Rat/LID
Abbreviations: DMBA,7,12-dimethylbenz[a]anthracene; ENU, ethyinitrosourea; NDEA,Nnitrosodiethylamine; TPA, 12-0-tetradecanoylphorbol 13-acetate.
aInformation in this column indicates the ontogenetic stage of the germ cells at which exposure occurred. For fetal gonocytes, GD is gestation day; for adults, days is days before mating. bUnless other-
wise indicated, one treatment was given at each ofthe times indicated. CSubstantial positive effects are listed, usually of statistical significance; [ ]bracket, negative effects; { } bracket, nochange.
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for the sensitive N5 strain, spermatogonia
were also affected (142). In C3H mice, 252Cf
irradiation had a larger effect on liver tumors
in offspring when given 14 days before mat-
ing, compared to 3 months before mating
(143,144). Exposures offetal male hamsters
to N-nitrosodiethylamine (NDEA) on GDs
13 and 14, but not 12 or 15, caused signifi-
cant increases in neoplasia in their offspring
(145). Thus, special sensitivity ofpostmeiotic
sperm, in which DNA repair does not occur,
seems likely, but all other stages are also vul-
nerable, in theory, depending on the exposure
agent and dose, genetic background, etc.
Less work has been carried out on precon-
ceptional exposure of females (Table 7).
Various intervals between 1 and 56 days
before mating, encompassing mature oocytes,
follicular stages, and primary oocytes, were
comparably sensitive to effects ofurethane,
whereas effects ofXrays were greatest between
8 and 21 days before mating, the postmeiotic
stages, with earlier treatment leading to steril-
ity (131). Mature oocytes, 1-7 days before
mating, were vulnerable only to high acute
doses ofX ray; fractionated doses were with-
out effect. Effects have also been noted after
transplacental exposure of mouse fetuses to
DES, with mid-gestation, late-gestation, and
neonatal treatment having similar effects on
the incidence ofvaginal tumors in the F2
descendants (146). Female hamster fetuses
were less sensitive than their brothers to a
multigenerational effect of transplacental
NDEA, with a significant effect noted only
after exposure on day 13 (145).
Walker and Kurth (147) carried out an
interesting experiment on the mechanism of
the multigenerational effect of DES in mice.
Because the initial exposure was to the germ
cell, the effect on the F2 descendants could be
mediated by an inherited genetic alteration,
or indirectly by changes in the F, female
developing from the germ cell (e.g., hormonal
alterations). To test this, Walker and Kurth
(147) transferred F2blastocysts among treated
and control mothers. They found that either
treatment ofthe blastocyst itself, or maternal
treatment as a germ cell, was sufficient to
cause an increase in uterine and ovarian
tumors in the F2 females as adults. These
effects appeared to be additive.
Thus, the rodent female germ cells, like
those ofthe male, have theoretical sensitivity to
preconceptional carcinogenic effects at every
developmental stage, with actual effects depen-
dent on agent, dose, and genetics, and with
both direct and indirect effects potentially
operative. The meaningfulness ofthese find-
ings for human riskwill not become clear until
the mechanisms are understood. Although
there is some evidence that preconceptional
carcinogenesis involves conventional gene
mutations showing Mendelian inheritance
(131,132,137,13-9, in many contexts the high
frequency ofthe effects and odd inheritance
patterns suggest that other novel mechanisms
are involved (148). Epigenetic alterations in
control of gene expression, as in genetic
imprinting, are a possibility (148); mutations
in microsatellites (14.9) are another.
Transplacenal andNeonaul
Carcinogenesis
Tables 8-21 summarize, by target tissue,
published literature in which different stages
ofprenatal and/or neonatal development have
been compared with regard to effects of
chemical or radiation exposure within the
same experiment. Each table also provides
information regarding the ontogeny ofthat
target tissue in rodents.
A numberoffactors have been suggested as
determining susceptibility at different stages.
These include a) numbers oftarget cells at risk,
b) sensitivity to cell killing, c) effects ofrate of
cell division on fixation of mutation before
repair can occur, d) ability to repair DNA
damage, e) expansion ofclones ofmutatedcells
as part of normal ontogeny, J) presence of
undifferentiated stem cells, g) development of
differentiated characteristics, including the
ability to carry out metabolic activation of
Table 7. Preconceptional carcinogenesis in animals: female exposure followed by mating with an untreated male.
Species/strain Germ cell stage atexposurea Exposure agent/doseb Site of neoplasmsc Reference
Mouse/ICR 64-80 days, primary oocyte X ray, 36-504 rad {No effect} (131,133)
1-7 days, mature oocyte {No effect, fractionated dose}; lung, increase
at 360 and 504 rad
8-14 days, 15-22 days, follicular oocyte Lung
22-28 days, primary oocyte {No effect}
Mouse/ICR Fetal day 15; youngest oocytes X ray, 216 Rad Lung after postnatal urethane treatment (133)
Mouse/MA Late gestation; primary oocyte formation DMBA, 400 pg/mouse Lung (215)
Mouse/CD-1 GD 9-16, or GD 18, or PN 1-5 DES, 2.5, 5, or 10 Uterine adenocarcinomas: all groups (146)
pg/kg; 1 mg/kg; or
0.002 pg/pup/day)
Mouse/ICR 1-7, 8-14, 15-22, 22-28, 29-35, 36-42, Urethane, 1 or 1.5 mg/g Lung (131)
43-49, 50-56 days; primary to mature oocyte
Hamster/SG GD 12-15, lx; primary oocyteformation NDEA, 10 mg/kg GD 13: increase in ratio malignant/benign (145)
tumors, male offspring
Abbreviations: DMBA,7,12-dimethylbenz[alanthracene; NDEA, N-nitrosodiethylamine. alnformation in this column indicates theontogenetic stage ofthe germ cells atwhich exposure occurred. For fetal gonocytes, GD is gestation day and PN is days after birth; for adults, days is days before
mating. lx indicates one exposure on each day. bUnless otherwise indicated, one treatment was given at each of the times indicated. cSubstantial positive effects are listed, usually of statistical signifi-
cance; [ ] bracket, negative effects; { } bracket, no change.
Table 8. Skin tumors after transplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mice/B6WHT GD 12 or 16-18 X ray, 200 R GD 16-18: papillomas (150)
Mice/NMRI GD 8-20, lx DMBA, 60 mg/kg; TPA as promoter postnatally GD 10-20: papillomas GD 19 (191)
Mice/HA GD 3-18, lx DMBA, 120 mg/kg, PN TPA 3x/week for 9 weeks GD 9-18: papilloma GD 15-18 (152)
Hamster/SG GD 7-14 ENU, 0.2 or 0.5 mmol/kg GD 9-14, 0.5 mmol/kg melanomas GD 12-13 (224)
Ontogeny of skin: Mouse-GD 14: earliest differentiation, with start of hair follicles; 15: two more skin layers form; 16: stratum corneum, and sloughing epidermis. Hamster-G 12: all three layers pre-
sent, primordia of hairfollicles; 13: skin wrinkled and loose, pads present on all feet.
Abbreviations: DMBA,7,12,-dimethylbenz[alanthracene; PN, days after birth; TPA, 12-0-decanoylphorbol-13-acetate.
aSensitivity range indicates the ontogenetic period during which exposure led to the appearance ofsignifiant numbers of skin tumors ofthe types indicated in the adultoffspring. Sensitivity highest indicates
the period during which the greatest numbers of skin tumors were initiated. bGD or PN ofexposure are indicated. lx indicates a single exposure on the days indicated.'he dose at each exposure isgiven.
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Table 9. Lung/upper airway tumors aftertransplacental or neonatal exposures in animals.
'9RPnziiitjha
Species/strain
Mouse/B6WHT
Mouse/B6C3
Mouse/ICR
Mouse/NMRI
Mouse/NMRI
Mouse/A/C 5
Mouse/ICR
Mouse/ICR
Mouse/ICR
Mouse/B6C3
Mouse/ICR
Mouse/B6C3
Mouse/B6C3
Mouse/B6
Mouse/C3HeB/FeJ
Mouse/C3HeB/FeJ
Mouse/C3HNCr
Mouse/SwissBW
Mouse/C3H
Mouse/AKR, SWR,
DBA, C57BL/6,
C57/L
Mouse/B6C3 and
C3B6
Mouse/SWR/AKR
Mouse/NIH Swiss
Mouse/NIH Swiss
Hamster/SG
Hamster/SG
Hamster/SG
Hamster/SG
Exposure periodb
GD 12 or 16-18
GD 17-PN 365,1x
GD 0-16,
or PN 1, lx
GD 12-16, 1x
GD 6-20, lx
GD 17-21, lx
GD 5-PN 5, 1x
GD 7-19, 1x
GD 9-17, 1x
Daily, GD 7-11,
11-15, or 14-18
GD 12, 15, and 18
or PN 1, 4, 7, 15,
18, and 21
GD 9-17, lx
GD 12,14,16, or 18
GD 12,14, 16, or 18,
orPN 1, 15, or42
GD 14, 15, or 17
GD 10, 13 or 15,
adult
GD 13-19 1x or
PN 5, 15, or 35
GD 14, 16, or 18
GD 15-19 lx
GD 16 or 19
GD 12-18, 1x
GD 12-18, 1x
GD 14-18, 1x
GD 15, 17, and 19
orPN 1,4,7,
10, and 14
GD 12-18 or PN 1-8
GD 10-15 lx
GD 12-14
GD 8, 10, 12, or 14
GD 8-15, lx
Agent/dosec
X ray, 200 R
y-ray, 137Cs, 3.8 Gy
X ray, 36 Rad, then
urethane on PN 21
5-Azacytidine, 1 or2
mg/mouse
DMBA, 60 mg/kg
Urethane, 25 mg/mouse
Urethane, 1 g/kg
Urethane 1 or 0.2 g/kg
4-NQO, 25 mg/kg
Urethane, 0.5 g/kg
Methyinitrosourethan,
5 mg/kg
ENU, 60 mg/kg
ENU, 60 mg/kg
ENU, 0.5 mmol/kg
ENU, 10, 25, or50 mg/kg
ENU, 35 mg/kg
ENU, 0.5 mmol/kg
ENU, 0.75 mmol/kg
NDMA, 7.4 mg/kg
NDEA, 51 mg/kg
ENU, 47 mg/kg
ENU, 0.5 mmol/kg
ENU, 0.5 mmol/kg
NDEA, 50 mg/kg
NNK, GD 100 mg/kg,
PN 50 mg/kg
AZT, GD 12.5 or25
mg/mouse or
PN 25, 50, 100, or
200 mg/kg
NDEA, 45 mg/kg
NDEA, 10 mg/kg
2-Hydroxypropyl-
propyinitrosamine;
2-oxopropyl-
propyinitrosamine
100mg/kgd
N-Nitrosobutylamine,
30 mg/kg
Range
GD 16-18
GD 17-PN 35
X ray alone, no effect
Increased susceptibility to
urethane, GD 0-14
GD 14(2mg only), 16
GD 10-20
17-21
GD 13-PN 5
GD 13-19
GD 13-17
GD 11-15 and 14-18
PN 1-21
GD9
All groups
All groups
All groups
GD 10-15
All groups
All groups
All groups
GD 19
GD 19
GD 16 or 19
AKR/J: GD 14-18
SWR/J: GD 12-18
DBA/2J: GD 14-18
C57BL/6J: GD 14-18
C57L/J: GD 14-18
GD 12-16
GD 16-18
PN
GD 12-18 and PN 1-8
GD 12-15: trachea, larynx, and
lung tumors
GD 14: trachea, larynx (papillomas
and neuroendocrine)
GD 14: laryngotracheal papillary
polyps
Tracheal and larynx: all groups
Highest
GD 16-18; fewer lung tumors in
male offspring from GD 12
GD 17
No significant differences
GD 16
GD 15-20
< 8 hr before birth
GD 15-19
GD 15, 17; 19 if < 12 hr before birth
GD 17
GD 14-18
GD 16
GD 16
GD 15
GD 15
Size greatest on GD 10
GD 16andPN5
More papillary tumors after GD
13-16 and PN 5 versus GD 17-19
Size greatest, GD 13
Size and progression greaterfor
GD 14 and 16
Postnatal increase in multiplicity
only after GD 18
GD 16, number of tumors
GD 15, size of tumors
GD 16
GD 16
GD 16
GD 16
GD 16
GD 16
GD 16
GD 18
No significant differences
GD 15
No significant differences
Ontogeny of lung: Mice-GD 9.5: lung buds appear; 11: bronchial structures in right lung; 14.5: lungs lobed and vascularized; 12-16: pseudoglandular, undifferentiated; 16: alveoli appear, growth rate
slows; 18: first appearance of Clara cell antigen. Hamsters-GD 9: lung buds appear; 10: three primary bronchi in right, two in left lung; 11: two prominent lobes in each lung; 12: manybronchi, some bron-
chioles appear; 13: fullyfunctional lung.
Abbreviations: AZT, 3'-azido-3-deoxythymidine; DMBA, 7,12-dimethylbenz[alanthracene; 4-NQO,4-nitroquinoline-N-oxide; NDMA, N-nitrosodimethylamine; NDEA, N-nitrosodiethylamine; NNK, 4-(methyl-
nitrosamino)-1-(3-pyridyl)-1-butanone; PN, days after birth.
&Sensitivity range indicates the ontogenetic period during which exposure led to the appearance ofsignifiant numbers of lung tumors in the adultoffspring. Mouse lung tumors were adenomas/carcinomas
derived from the epithelial cells of the periperal lung. Sensitivity highest indicates the period during which the greatest numbers of lung tumors were initiated. bGD or PN of exposure are indicated; lx
indicates a single exposure on each ofthe days indicated. cThe dose at each exposure isgiven. dMethylpropyinitrosamine, N-nitroso-bisl2-hydroxypropyl)amine, and4-hydroxybutryl-butyinitrosamine did
not show this.
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Reference
(150)
(165)
(234)
(210)
(191)
(235)
(155)
(155)
(155)
(153)
(155)
(153)
(185)
(235)
(179,237
(238)
(181)
(162)
(18i)
(239)
(220)
(240)
(190)
(233)
(183,184,241)
(145)
(185)
(2421
Otil lbiLIV]ly-
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chemicals, h) metabolic detoxification by
placenta and/or maternal tissues, i) metabolic
detoxification by the perinate itself, and
j) immaturity of the endocrine and immuno-
logical systems. There is some experimental
evidence for all ofthe above except forj, but
this evidence is largely correlative in nature,
and, albeit quite convincing in somesituations,
is in no case definitive. Several ofthese factors
pertain concurrently. Rapid rate ofcell division
during organogenesis, the presence of numer-
ous stem cells, the potential for generation of
mutant clones, and limited placental develop-
ment all characterize the midde third ofgesta-
tion in the rodent, whereas the maximum
number ofcells at risk and the development of
differentiated features are both features ofthe
late fetus. Thus even strong correlative evi-
dence must be interpreted with caution. It is
also clear that likely factors are species, strain,
tissue, and agent specific.
Numbers ofcels at risk. Intuitively, it is
clear that for a given dose of carcinogen and
radiation, the likelihood of a mutational car-
cinogenic event will increase as a function of
the number oftarget cells ifall other factors are
equal. This has been confirmed as likely for
mouse skin throughout its development in the
last half of gestation (Table 8), with X ray
(150) or 7,12-dimethylbenz[a]anthracene
(DMBA) (151,152) as the carcinogenic agents.
Sensitivity was greatest at the end ofgestation,
when numbers oftarget cells are highest, and
Morris et al. (152) further ruled out metabolic
activation of DMBA as a likely contributing
factor by studies ofmacromolecular adducts of
the chemical.
A similar result was obtained for mouse
lung tumors caused by the direct-acting
chemical ENU, but for a more limited devel-
opmental period (GDs 12-16), a period of
exponential growth of undifferentiated
pseudoglandular lung tissue (153). Peak
ENU sensitivity of the mouse fetal lung on
GD 16 has been demonstrated in many
experiments (Table 9).
Sensitivity ofcells to killing. During
some stages ofontogeny, especially those with
high rates ofcell division, cells may be exquis-
itely sensitive to killing or growth suppression
by genotoxic and other agents. It has been
suggested that apparently low responsiveness
to tumorigenesis during these times may indi-
cate the destruction ofsensitive cells, leading
to a loss oftarget cells with neoplastic poten-
tial. Thus, cytotoxic radiation treatment
before ENU exposure during late gestation of
rats resulted in lower incidence of ENU-
caused brain tumors (154). On an organism
level, teratogenicity or embryonic death may
be a more likely outcome than initiation of
neoplasia during these stages. This has been
studied systematically for urethane, for which
mouse embryos that survived the toxic effects
did not develop tumors (155,156). Other
chemicals and species have not been exam-
ined in detail for similar outcomes. Although
a reduction in cell division after irradiation
during organogenesis has been documented
(157), an influence of this effect on tumor
yield has not been demonstrated.
Effects ofrates ofceUldivision. Based on
studies with cultured cells (158,159), sensitiv-
ity to mutation (and hence to initiation of
neoplasms) can be directly proportional to
mitosis rate because ofincreased frequency of
fixation of mutation by replication before
repair can occur. Recently, it was empirically
demonstrated that the rate ofmutation in the
hamster embryo is maximum on GD 6, cor-
responding to the highest rate ofcell division
(160). The calculation oftumors induced per
target cell per embryo or fetus for the rat, or
per total cells for the hamster, confirmed that
the risk per cell decreased as gestation pro-
gressed (161). The strongest correlative
demonstration ofthis effect was provided for
ENU initiation oflung tumors in fetal Swiss
mice between GDs 15 and 19: numbers of
adenomas induced were strongly correlated
with numbers ofcells in the cell cycle (162).
However, the fact that the correlation was
noticeably stronger for cells in G1 compared
to S or G2 + M phases ofthe cell cycle sug-
gests that factors in addition to DNA repair
were important.
Table 10. Ovarian tumors aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mice/B6/WHT GD 12 or 16-18 X ray, 200 R GD 16-18: granulosa cell tumors, (150)
hemangiomas, epidermoid
carcinomas, cystadenoma
Mice/NMRI GD 11-13 or 14-16 X ray, 0.88-1.2 Gy GD 14-16: tubularadenomas, (157)
granulosa cell tumors, luteomas
Mice/B6C3 GD 17, PN 0-365, 1x y-Ray,137Co, 3.8 Gy All groups PN 0 (165)
Mice/NMRI GD 6-20, 1x DMBA, 60 mg/kg Granulosa cell tumors, all groups GD 8-13 (191)
Mice/ICR GD 7-17 1x or8, 9, Urethane, 0.2 or 1 g/kg Cystadenoma: GD 13, 1x, 8-10, 3x, No significant difference (229)
and 10 and 12-14, 3x
or 12, 13, and 14
or 16, 17 and 18
Mice/B6C3 GD 7-11, 11-15, Urethane, 0.5 g/kg All groups: granulosa cell tumors GD 7-11 (153)
or 14-18 and tubular adenomas
Mice/B6C3 GD 12, 14, 16, or ENU, 60 mg/kg All groups-prenatal: tubular GD 14, PN 1 (188)
18 or PN 1, 15, adenomas; postnatal:
or 42 granulosa cell tumors
Mice/B6C3 GD 12, 14, 16, or ENU, 0.5 mmol/kg All groups GD 12, 14 (220)
and C3B6 18
Rat/Wistar GD 14, 18, or 20 N-Nitrosobis(2- All groups: luteoma, adenoma, GD 18 (no tumors ofthyroid (251)
oxopropyl)amine, granulosa cell tumor, thecoma, or kidney, the tumors found
20 mg/kg angiosarcoma in adult rats)
Mice/NMRI GD 12, 14, or 16 5-Azacytidine, 1 or 2 mg/kg GD 12 (2 mg) or 16(1 mg): decrease GD 12 (210)
Mice/NIH Swiss GD 12-18 or PN AZT, GD 12.5 or25 Both groups: granulosa and thecal GD 12-18 (233)
1-8 mg/mouse cell tumors, adenomas
PN 25, 50, 100, 200 mg/kg
Ontogeny of the ovary: Mouse-GD 8: primordial germ cells in yolk sac; 9-10: germ cells arrive at genital ridge by migration, are undergoing extensive mitosis; 11: cortical proliferation ofovary: 13: mei-
otic prophase in ovary, until GD 16; 14/15: leptotene/zygotene, high rate of oogonial division. Ovary becomes vascular; 16/17: pachytene; birth: some follicle cells; PN 3: static dictyate stage. Rat-GD
10.5-12.5: primordial germ cells migrate to genital ridges; 14.5: sexdifferentiation; 17: oogenesis complete, prophase of meiosis.
Abbreviations: AZT, 3'-azido-3'-deoxythymidine; DMBA, 7,12,-dimethylbenz[alanthracene; PN, days after birth.
"Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of signifcant numbers of ovarian tumors of the types indicated in the adult offspring. Sensitivity highest indicates
the period during which the greatest numbers ofovarian tumors were initiated. bGD orPN of exposure are indicated. lx indicates a single exposure on thedays indicated. dThe dose ateach exposure is given.
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Influence of rate ofcell division has also
been suggested for the ovary, for which late
embryos or middle-gestation mouse fetuses
are more susceptible than those oflater gesta-
tion to tumor initiation by urethane, ENU,
DMBA, or azacytidine, but not those caused
by radiation or a nitrosamine (Table 10).
Interpretation ofresults for the ovary are com-
plicated by the possibility that these are caused
byindirect hormonally mediated effects (163).
The mouse embryo and early fetus were
the most susceptible to causation oflympho-
cytic leukemias and lymphomas by DMBA,
whereas GD 16 treatment with ENU or
5-azacytidine gave the highest yield ofthese
malignancies (Table 11). However, the day 17
mouse fetus was not susceptible to causation
oflymphoma or myeloid leukemia at doses of
y-rays effective in the neonate or adult
(164,165). Findings for the nervous system
and nitrosoureas, as related to the stage of
greatest sensitivity, have also been mixed
(Table 12).
Ability to repair DNA damage. This
characteristic has been studied mainly for
O-alkylated DNA bases, the principal muta-
genic DNA lesions produced by many car-
cinogenic alkylating agents. 06- alkylguanine
is a major promutagenic adduct resulting from
the reaction of ENU or methylnitrosourea
(MNU) with DNA. Repair ofthis lesion by
06-alkylguanine-DNA alkyltransferase occurs
at a considerably slower rate in the fetal rat
brain, the target organ, than in other tissues
(166-168). The level ofthe enzyme is maxi-
mum on GD 12, and decreases thereafter
(169). However, this repair deficiency is simi-
lar in the adult (170), so it cannot account for
the 50-fold greater sensitivity ofthe develop-
ing nervous system to tumor initiation by
ENU. Similarly, this repair enzyme is lower in
the brains ofmice and gerbils than in liver and
other tissues (171), but few neurogenic
tumors are initiated in these species.
Repair in DNA strand breaks caused by
methylmethansulfonate was much less for
fetal rat brain cells in culture compared to
mouse brain and rat and mouse liver cells
(172). The repair capacity for 06-methylgua-
nine was also very poor in fetal rat kidney
compared to liver (168). Also in rats, DNA
Table 11. Lymphoid neoplasms aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mouse/RF
Mouse/B6/WHT
Mouse/B6C3
Mouse/BALBc
Mouse/NMRI
Mouse/B6C3
Mouse/B6C3
Mouse/DBA/2J,
C57BL/6J,
C57L/J, SWR/J
Mouse/B6C3
Mouse/B6C3
Mouse/NIH Swiss
Mouse/Swiss
Mouse/NMRI
Mouse/CD-1 Swiss
Dog/beagle
GD 17-PN 180,
lx
GD 12 or 16-18
GD 17, PN 0-364,
lx
GD 14 or adult
GD 6-20, 1x
GD 12, 15, and 18;
orPN 1,4,7, 15,
18 and 21
GD 12,14,16, or
18; PN 1, 15, or42
GD 12, 14,16, or 18
GD 12,14,16, or 18;
PN 1,15, or42
GD 12, 14, 16, or
18 or PN 1,15,
or42
GD 16 or 19
GD 1-7, 8-14, or
15-22
GD 12, 14, or 16
G 12-18orPN
1-8
GD 8, 28, or 55 or
PN 2
X ray, 100, 200 or
300 R
X ray, 200 R
y-Rays, 137Cs, 3.8 Gy
a-Radiation, 241Am,
100, 500, or 1,500
Bq/g (GD) or45-213
Bq/g (PN)
DMBA, 60 mg/kg
Urethane, 0.5 g/kg
ENU, 60 mg/kg
ENU, 0.5 mmol/kg
ENU, 60 mg/kg
ENU, 60 mg/kg
NDMA, 0.1 mmol/kg
Carbendazim, 500
mg/kg + nitrite,
0.05% DW
5-Azacytidine, 1 or 2
mg/kg
AZT, GD 12.5 or 25
mg/mouse
PN 25, 50, 100, 200
mg/kg
y-Ray, t0Co, 16 or 83
cGy
Thymic lymphoma: PN 1-180
myeloid leukemia: PN 14-180
GD 12: decrease in nonthymic lymphoma
and reticulum cell sarcoma
Lymphoma: PN 0-105
Histiocytic sarcoma: decrease, GD 17-PN
240
Myeloid leukemia: PN 35-365
GD 14, males only
GD 6-15
PN 1-7
GD 16-PN 42
PN 40
PN 70
PN 35
GD 17
PN 105
GD 11 (males), GD 6-11
(females)
PN 1-7
PN 42
DBA/2: GD 14-18
C57BL/6J: GD 14-18
C57L/J: GD 14-18
SWR: GD 12-18
GD 12-PN 42
GD 12-PN 42
Histiocytic sarcoma: GD 19
GD 1-7,8-14, or 15-22
GD 12, 1 mg/kg and GD 16, both doses:
leukemia/lymphoma increase
GD 12, 2 mg/kg and GD 14, both doses:
leukemia/lymphoma decrease vs. controls
Histiocytic sarcoma: females GD 12-18
only
Lymphoma (lymphoblastic, follicle center
cell), decreased, both sexes and dose
periods
Lymphoma/leukemia: GD 55
GD 16
GD 16,18
GD 16,18
All similar
GD 16, PN 42
(terminated at 36 weeks)
Males: PN 42
Females: PN 15, 42
(at natural death)
No significant difference
Increase: GD 16, 1 mg/kg
Decrease: GD 14, 2 mg/kg
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(164)
(150)
(165)
(243)
(191)
(153)
(153)
(2391
(153)
(188)
(1891
(244)
(210)
(233)
(245)
Ontogeny of the lymphoid system: Mouse-GD 11-12: first appearance ofthymus; 13: lymphocyte precursors seen in thymus; 14-15: rapidgrowth and histogenetic and organogeneticchange inthymus;
15: myelopoiesis in spleen; 16: myelopoiesis in marrow; 17: fetus versus adult: 10% of leukocytes, 50% oflymphocytes, 200% more young lymphocytes; 18: thymus is natal size.
Abbreviations: AZT, 3'-azido-3'-deoxythymidine; DMBA, 7,12,dimethylbenz[a]anthracene; DW, drinking water; NDMA, N-nitrosodimethylamine; PN, days after birth.
&Sensitivity range indicates the ontogenetic period during which exposure led to the appearance ofsignificant numbers ofhematopoietic neoplasms ofthetypes indicated in the adultoffspring. Sensitivity
highest indicates the period during which the greatest numbers of hematopoietic neoplasms were initiated. bGD or PN of exposure are indicated; lx indicates a single exposure on each of the days
indicated. She dose at each exposure is given.
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repair involving unscheduled DNA synthesis
after MNU was more rapid in adults than in
newborns and was not detected in fetuses
(173). Repair of 06-methylguanine was lower
and levels of this adduct higher in newborn
mice compared to adults given the same dose
of N-nitrosodimethylamine (NDMA) (174).
Human fetal cells in early passage showed dif-
ferences in the extent ofDNA excision repair
after ultraviolet irradiation or ENU; skin and
intestine were more active than liver, kidney,
and brain (175).
However, certain other DNA repair
enzymes are quite active in fetal tissues.
Apurinic apyrimidinic endonuclease had
expression throughout the rat fetus, with very
high levels in fetal thymus, liver, and brain
(176). The T:G mismatch-specific glycosylase
was ubiquitously expressed in mouse fetuses
up to GD 13.5, with high expression in the
nervous system, thymus, lung, liver, kidney,
and intestine by GD 14.5; at later stages it was
prominent in thymus, brain, nasal epithelium,
and proliferating regions of other tissues
(172). The activity of8-oxo-2'-deoxyguanosine
5'-triphosphate pyrophosphohydrolase,
which eliminates oxidatively-damaged guano-
sine triphosphate, was higher in fetal mouse
liver and lung than in the same tissues ofthe
mothers (178).
In sum, comparative levels ofDNA repair
enzymes may influence the susceptibility of
perinatal tissues to carcinogenesis, but defini-
tive experimental evidence establishing this
connection is still lacking.
Expansion ofclones ofinitiated cells.
After an embryonic or fetal cell sustains a
mutation, the normal cell divisions of
ontogeny may lead to expansion of the
mutated (initiated) cell into a clone. This may
reduce the latency of resulting tumors and
increase the chances for furthergenetic changes
needed for transformation ofthe initiated cells
into a growing tumor. Also, the cells ofthe
clone might be costimulatory for neoplastic
development through paracrine factors. After
transplacental ENU in mice, the lung and liver
tumors initiated on day 10 are few in number
because ofthe small target cell population but
much larger and phenotypically unique com-
pared to those initiated later (179). Similarly,
lung tumors initiated by ENUon GD 15 were
larger (162,180,181), more easily transplanted
(180), and more papillary in phenotype (181)
compared to those initiated later in gestation.
This was also demonstrated for urethane-
induced tumors (156), which were more likely
to be ofpapillary type than those induced in
their mothers.
Presence ofundifferentiatedstem cells.
Evidence for a role for undifferentiated stem
cells is strongest for fetal kidney (Table 13).
The perinatal chemical induction in rats of
nephroblastomas, which are similar to the
Wilms' tumors ofchildhood, may require the
presence ofkidney stem cells. These tumors
Table 12. Nervous system tumors aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mouse/B6C3 and GD 12-18, lx ENU, 0.5 mmol/kg GD 12-18 GD 12-14 (220)
C3B6
Mouse/C3Hf/HeN GD 12, 13, 14, 16, ENU, 0.5 mmol/kg GD 12-14 No significant difference (248)
or 18
Mouse/C3HNeNC GD 16 or 19 ENU, 0.4 mmol/kg Schwannomas: both groups GD 19 (189)
MTV- Glioblastomas: GD 19
Rat/BDIX GD 8-16 or 16-23 ENU, 0.5 mmol/kg GD 16-23 (249)
Rat/BDIX GD 6-22, lx ENU, 20 mg/kg GD 11-20 GD 16-22 (250)
Rat/BDIX GD 12-20, 1x ENU, 0.5 mmol/kg GD 13-20 GD 16-20 (249)
Rat/BDIX GD 15 or 22 ENU, 5 mg/kg Both groups No significant difference (187
Rat/Wistar GD 16, or PN ENU, 40 mg/kg Gliomas and glioependymomas: all GD 16 (223)
0-28, 1x groups
Rat/BDIX GD 15 or 22 ethyinitrosobiuret, Both groups No significant difference (187
100 mg/kg
GD 15 or23 1- phenyl-3,3,- Both groups GD 23
dimethylhydrazine,
25 mg/kg
GD 11 or 22 Azoxymethane, 20 GD 22
mg/kg
GD 15 or 21 methyl-2- Both groups GD 21
benzylhydrazine
40% of LD50
PN 1, 3, 10, 30, Azoxymethane All groups PN 1
or60, or adult
Rat/Wistar GD 12, 14, 16, or 18 MNU, 40 mg/kg GD 14 (221)
Hamster/SG GD 7-14 lx ENU, 0.2 or 0.5 mmol/kg GD 8-14 Females: PNS tumors shorter (224)
latencywith GD 9-11
Other, both sexes and doses: GD 14
Oppossum PN 0, 7, 14, 21, ENU, 100 mg/kg Intraocular medulloepitheliomas: No significant difference (182)
28, 42, 56, 70, 84, PN 7-20
or 112 Brain gangliogliomas: PN 0
Rabbit GD 8 or 10, or ENU, 50 mg/kg (GD 8, Gliomas, schwannomas: all groups GD 8 (225,226)
10-19 or 1S-24 10) or60 mg/kg
(GD 10-19, 15-24)
Ontogeny of the nervous system: Mouse-GD 9.5: brain divisions apparent, spinal cord well differentiated; 11: rapidly proliferating neuroblasts. Cranial and spinal ganglia formed. Spinal cord more orga-
nized; 14: structures of brain in place (olfactory lobes, optic chiasma, pituitary, and cerebellum); 15: rapid growth of cerebrum. Rat-GD 8-9: neural plates appear; 11: three brain vesicles present; 13:
cerebral hemispheres present, choid plexuses in first, second, and fourth ventricle; 15: choroid plexus in third ventricle; 17: choroid fissure completely closed; 20: corpora quadrigemina recognizable in the
mesencephalon. Hamster-GD 8.5: brain divisions apparent; fifth and combined seventh/eighth cranial nerve ganglia appear; 10: beginning of growth and differentiation. Rabbit-GD 8: neural plates
appear; 10: neuropores closed, three brain vesicles appear; 11: cerebral hemispheres appear; 15: olfactory bulbs formed, cerebellum recognizable.
Abbreviations: tD50, median lethal dose; MNU, methyinitrosourea; MTV-, mammary tumorvirus negative; PN, days after birth; PNS, peripheral nervous system;
aSensitivity range indicates the ontogenetic period during which exposure led to the appearance of signifcant numbers of neurogenic tumors of the types indicated in the adult offspring. Neurogenic
tumors in mice after perinatal ENU were, in order of frequency of type: neurinoma, oligodendroglioma, medulloblastoma, astrocytoma, other; in order of frequency of site: peripheral and cranial nerves,
cerebrum, spinal cord, pons, cerebellum, cauda, and meninges. Sensitivity highest indicates the period during which the greatest numbers of neurogenic tumors were initiated. bGD or PN of exposure are
indicated. lx indicates a single exposure on the days indicated. cThe dose at each exposure is given.
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are not seen after transplacental exposure of
mice, which establish a fully differentiated kid-
ney by GD 17-18, or ofhamsters, which have
a functional kidney by GD 13. In the rat, on
the other hand, stem cells are present until a
few days after birth, and nephroblastomas are
induced after exposure to ENU or MNU, with
a maximum on GD 18 when fetal kidney
reaches its peak size. However, some strains of
rat (e.g., Noble) are more susceptible than oth-
ers (F344 and Wistar), indicating the opera-
tion of additional genetic factors. In the
opossum, organ development takes place
mainly after birth, with kidney metanephric
stem cells apparent for 6 weeks, and this tissue
is sensitive to causation of nephroblastomas
throughout this period (182). In rabbits,
nephroblastomas are inducible by ENU, along
with tubular cystadenomas, throughout the
last 2 weeks ofgestation (after a fully differen-
tiated kidney is present). Information is lack-
ing regarding the presence of stem cells in
rabbit kidney during this time.
Development ofdifferentiated charac-
teristics. For some tissues and carcinogens,
sensitivity increases markedly toward the end
ofgestation, as the tissue expresses more ofits
adult differentiation characteristics. This was
studied systematically for hamster trachea,
where tumorigenesis by NDEA correlated
strongly with reduced rate ofmitosis and pres-
ence of rough endoplasmic reticulum and
secretion of mucopolysaccharide (183,184).
Several other nitrosamines were also most
effective in causation of laryngotracheal
tumors on the last day of gestation in the
hamster (185). Increased sensitivity at the end
of gestation or in the newborn has been
demonstrated for NDMA (186) and
1-phenyl-3,3-dimethyltriazene in rat kidney
(187), NDMA and NDEA in mouse lung and
liver (188-190), ENU and schwannomas and
glioblastomas in C3H mice (189), several
hydrazines and neurogenic tumors in rats
(187), ENU and intraocular medulloepithe-
liomas in opossums (182), DBMA and
forestomach and benign uterine tumors in
mice (191), ENU and nephroblastomas in
rabbits (192,193), and a variety ofcarcinogens
in pituitary (Table 14) and forestomach
tumors by DMBA (Table 15).
Table 13. Kidney tumors after transplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mouse/B6C3 GD 12, 14, 16, or 18 ENU, 0.5 mmol/kg Papillary adenomas No significant difference (220)
and C3B6 all groups
Rat/BDIX 7x, gestation week NDMA, 1 mg/dose Gestation week 3 - (186)
1,2, or3
Rat/BDIX GD 15 or 23 1-Phenyl-3,3,-dimethyltriazene, Both groups GD 23 (187
75 mg/kg
Rat/BDIX GD 11 or22 Azoxymethane, 20 mg/kg GD 22 (187
Rat/Wistar GD 12, 14, 16 or 18 MNU, 40 mg/kg GD 14-18 GD 18 (nephroblastoma) (221)
Rat/Nb GD 10-18 lx or ENU, 0.5 mmol/kg Nephroblastoma: Nephroblastoma: GD 18 (222)
PN 1-10lx GD 14-18, PN 1-3
Renal mesenchymal: Renal mesenchymal: PN 7
PN 1-10
Rat/Wistar GD 9-16 lx or PN ENU, 40 mg/kg Renal mesenchymal: PN 0-28 (223)
all groups
0-281x
Hamster/SG GD 8-14 1x ENU, 0.2 or 0.5 mmol/kg Tubular adenomas and GD 13 (224)
carcinomas, GD 12-14
Rabbit GD 18, 21-22, 25-26, ENU, 60 mg/kg (GD 18) Renal tubular cystadenomas, GD 18 (225,226)
or30-31 or 50 mg/g (GD 21-31) nephroblastomas: all groups
Opossum PN 0, 7, 14, 21, 28, 42, ENU, 100 mg/kg Nephroblastomas: PN 0-42 No significant differences (182)
56,70, 84, or 112
Ontogeny of kidney: Mouse-GD 8: nephrogenic cords; GD 10: pronephric tubules and ducts; GD 12: mesonephric tubules and ducts, early metanephroi; GD 14-15: metanephric kidney structure estab-
lished; GD 17-18: fully differentiated and functional kidney. Rat-GD 12-14: renal rudiments, ureteric bud surrounded by loose mass of metanephric mesenchyme; GD 14-18: collecting ducts and
glomeruli appear and increase,, maximum at D 18; mesenchyme is still abundant; PN 10: a few primitive structures still present, high mitotic activity. Hamster-GD 8: a few rudimentary mesonephric
tubules, many remaining solid; GD 9: numerous rudimentary, solid mesonephric tubules; GD 10: maximum nonfunctional mesophroi, pelvis of metanephros dividing, surrounded by mesenchyme; GD 12:
Bowman capsule forming, noglomeruli; GD 15: functional kidney. Rabbit-GD 8.5: prenephric tubules appear, mesonephric ducts and tubules appear on day 9; GD 11.5: mesonephric duct enters urinogeni-
tal sinus, uteric buds formed; GD 13-14: metanephric kidney structure established; GD 18: fully differentiated kidney. Opossum-functional mesonephric kidney at birth; metanephric kidney is small, with
stem cells predominating; rapid nephrogenesis ensues, with nephrons at all stages ofdifferentiation by 1 week, and a functional kidney by 2 weeks, butmetanephric blastema still apparent until 6 weeks.
Abbreviations: NDMA, N-nitrosodimethylamine; MNU, methyinitrosourea; PN, days after birth.
aSensitivity range indicates the ontogenetic period during which exposure led to the appearance ofsignificant numbers of kidney tumors ofthe specified type in the adult offspring. Sensitivityhighest indi-
cates the period during which the greatest numbers of kidney tumors were initiated. bGD or PN of exposure are indicated; lx indicates that exposure was given once on each of the indicated days. "The
dose at each exposure isgiven.
Table 14. Pituitary tumors aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mice/B/WHT GD 12 or 16-18 X ray, 200 R GD 16-18 (150)
Mice/B6C3 GD 17, PN 0-365, y-Ray, 137Co, 3.8 Gy GD 17-PN 7 GD 17 (165)
lx
Mice/CD-1 GD 16 or 17 DES, 1 or 2mg/kg GD 16, 16 hr-GD 17, 16 hr GD 17, 16 hr (252)
Rat/F344 GD 17 or 16 and Nickel acetate, 90 pmol/kg (GD 17) GD 16 and 18 (253)
or45 pmol/kg (GD 16 and 18)
Ontogeny of the pituitary: Mouse-GD 8.5: hypophyseal pouch; GD 11.5: infundibular evagination of diencephalon; GD 14: pars distalis and intermedia distinguishable; GD 16: pars neuralis; GD 17: appears
secretory, clearlyendocrine by GD 18. Rat-GD 10.5: Rathke's pouch make contactwith infundibulum, forming the primordium of thehypophysis; 11.5: adenohypophysis (glandularportion ofpituitary)develops.
PN, days after birth.
&Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of significant numbers of pituitary tumors of the types indicated in the adult offspring. Sensitivity highest
indicates the period during which the greatest numbers of pituitary tumors were initiated. bGD or PN of exposure are indicated. lx indicates a single exposure on the days indicated. "The dose at each
exposure is given.
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Some treatments are markedly more effec-
tive postnatally than transplacentally. These
include urethane and ENU for causation of
Harderian gland tumors in mice (Table 16);
ENU and renal mesenchymal tumors in rats
(Table 13); 4-(methylnitrosamino)-1-(3-
pyridyl)-1-butanone and lung and liver
tumors in mice (Tables 9, 10, and 11); irradi-
ation, urethane, and ENU and lymphoid
tumors in mice (Table 11); radiation, ENU,
benzidine, and safrole and liver tumors in
mice (Table 17); 3'-azido-3'-deoxythymidine
and mammary tumors in mice (Table 18);
radiation and osteosarcoma in mice (Table
19), radiation and thyroid tumors in dogs
(Table 20), and DES and uterine tumors in
mice (Table 21). Certain types oftumors are
more readily caused in adult than in neonatal
animals (194), and certain chemicals are more
effective in adult than in neonatal mice (195).
Progressive acquisition ofdifferentiated char-
acteristics is among the several possible con-
tributing factors, along with numbers ofcells
at riskandeffective dose.
A differentiated character that can influ-
ence susceptibility to perinatal carcinogenesis
is the ability to activate chemically stable car-
cinogens to reactive DNA-damaging interme-
diates. This process is most often dependent
on cytochrome P450s, which in rodents
make their appearance during the last several
days ofgestation. In mice, metabolism of
NMDA increased steadily in fetal livers from
GD 16, where it was 3% of adult levels,
through day 19 (13%), postnatal day 1
(25%) and day 4 (50%), reaching adult levels
by day 7 (196). In human embryos, NDMA
demethylase was detectable by 5-6 weeks
after conception, and had increased 3-fold by
11-12 weeks (197). Also in mice, the genetic
ability to respond to inducers ofcytochrome
P4501A1, which metabolizes polycyclic aro-
matic hydrocarbons, determined numbers of
lung and liver tumors induced by 3-methyl-
cholanthrene and DMBA [but, interestingly,
not benzo(a)pyrene (BP)] (198-200), con-
firming that metabolic activation ofcarcino-
gens is a limiting factor in transplacental
carcinogenesis for at least some chemicals.
For metabolism-independent oncogenic
agents, such as ENU and radiation, it is obvi-
ous that factors other than cytochrome P450
levels must be operative ifstate ofdifferentia-
tion is in fact important. An influence ofdif-
ferentiation state, as opposed to total number
oftarget cells, seems most likely for tumor
types inducible only during or after differenti-
ation, as for intraocular medulloepitheliomas
in opossums after ENU; Harderian gland
tumors in mice after ENU; and myeloid
leukemias in mice, mammary tumors in rats,
and thyroid adenocarcinoma in dogs after
irradiation. A change in the target cell within
the organ also suggests a role for cellular dif-
ferentiation. For example, ovarian tumors
caused by ENU in mice were more likely to
be tubular adenomas after prenatal exposure,
but granulosa cell tumors after postnatal treat-
ment (188). In rats, ENU caused nephroblas-
tomas before birth but renal mesenchymal
tumors after birth. Mechanistic information is
notavailable foranyofthese situations.
Maternal/placental metabolism. Even if
fetal tissues are unable to carry out metabolic
activation ofcarcinogens, in certain cases a
chemical may be activated by the maternal
liver and the reactive intermediate delivered
transplacentally to the fetus. The strongest
case for such a situation was made in rats for
procarbazine, which was adducted to DNAof
fetuses but not to DNA ofdirectly exposed
neonates (201). After administration ofBP to
either pregnant mice (202) or pregnant patas
monkeys (203), the levels of 3 P-postlabeled
DNA adducts were similar in placenta and all
fetal tissues, in spite ofwide differences in the
abilities ofthese tissues to activate BP, sug-
gesting transplacental passage ofmaternally
activated BP derivatives.
Although maternal metabolism can
contribute to fetal risk in this way, detoxify-
ing metabolism is in general more important.
Mouse fetuses were more at risk oftranspla-
cental carcinogenesis by 3-methylcholan-
threne or DMBA iftheir mothers were not
responsive to induction ofdetoxifying metab-
olism of these compounds (198-200).
Placental metabolism also contributes to
detoxification: methylnitrosourethane was an
effective transplacental lung carcinogen in
mice only on GD 9. This was related to the
presence thereafter of effective hydrolase
activity toward this compound in placenta, so
that none reached the fetus afterday 9 (204).
Perinataldetoxification. Urethane was
10-fold more effective at causing mouse lung
tumors ifadministered < 12 hr before birth
versus 24 hr before birth. Several investiga-
tions showed that this correlated perfectly
with a 10-fold increase in total dose over time
in the neonate, which cleared the urethane
much more slowly than the pregnant mother
(205,206). This important principle has not
been studied for any other carcinogen but
almost certainlypertains to most ifnot all that
are chemically stable: most ofthe cytochrome
P450 and the phase II detoxification enzymes
(glucuronidases, epoxide hydrolases, etc.) are
low in amount at birth, and reach adult
levels only after 1-3 weeks. Poor capacity for
Table 15. Tumors in forestomach, intestine, pancreas, ortestis aftertransplacental or neonatal exposures in animals.
Sensitivitya
Tissue Species/strain Exposure periodb Agent/dosec Range Highest Reference
Forestomach Mice/NMRI GD 6-20 lx DMBA, 60 mg/kg GD 18-20 GD 19-20 (191)
Intestine Mice/min PN 5-35, lx ENU, 50 mg/kg All groups PN 5-14 (25)
Pancreas Hamster GD 8-14 ENU, 0.2 or0.4 mmol/kg GD 8-14 No significant difference (224)
Testis Rat/Wistar GD 14, 18, or20 N-Nitrosobis-(2- Glandulartype: GD 14-20 No significantdifference (251)
oxopropyl)amine
Abbreviations: DMBA, 7,12-dimethylbenz[a]anthracene; PN, daysafter birth.
aSensitivity range indicates the ontogenetic period during which exposure led tothe appearance of significant numbers ofthe tumortypes indicated in the adult offspring. Sensitivity highest indicates the
period during which the greatest numbers oftumors were initiated. bGD or PN ofexposure are indicated. 1x indicates a single exposure on the days indicated. c1he dose ateach exposure is given.
Table 16. Harderian gland tumors aftertransplacental orpostnatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mouse/NMRI GD 6-20 lx DMBA, 60mg/kg GD 17-20 GD 17-19 (191)
Mouse/B6C3 GD 17 or PN 0, 7, 35, 105, 240, or365 -tRays, 137Cs, 1.9-5.7 Gy PN 7-365 PN 35-105 (165)
Mouse/B6C3 GD 12, 15, and 18 orPN 1, 4, 7, 15, 18, and 21 Urethane, 0.5 g/kg PN only - (153)
Mouse/B6C3 GD 12,14,16, or 18, or PN 1,15, or42 ENU, 60 mg/kg PN 1-42 PN 15-42 (188)
Mice: Cellularmorphologyofthe Harderian gland changes from lowcuboidal to high columnarand functional differentiation ensues afteropening ofthe eyelids, PN day 12.
Abbreviations: DMBA,7,12-dimethylbenz[a]anthracene; PN, days after birth.
"Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of significant numbers of Harderian gland tumors in the adult offspring. Sensitivity highest indicates the period
duringwhichthegreatestnumbers oftumorswere initiated. bGDorPN ofexposure are indicated; lx indicatesthatexposurewas given once on each ofthe indicated days. 'The doseateachexposure isgiven.
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metabolic detoxification is probably one ofthe
major reasons for the high sensitivity ofthe
neonate to chemical carcinogenesis.
Endocrine or immunological control of
neoplasia development. Because endocrine
and immunological systems are undeveloped
in the perinate, it is possible that their
absence permits the establishment of neo-
plasms that would be suppressed in adults.
Although this idea is feasible, no concrete
supporting evidence has been presented. A
related concept is that perinatal exposures
have long-term effects on the endocrine or
immunological systems, which influence
postnatal tumor development. This is an
important possibility but has not been
extensively explored. The exposure of fetal
rats to DES led to an earlier appearance of
mammary tumors caused by postnatal
DMBA, and this effect was greater for DES
given on GDs 10-13 compared to GDs
15-18 (207). This could have involved a
direct effect of the DES on the mammary
tissue, an indirect endocrine effect, or both.
As noted previously, the multigenerational
effect of DES could be mediated both
directly by exposed blastocysts and by the
maternal gestational environment (147). A
number of plant-derived and anthropogenic
compounds have endocrine-disrupting activ-
ity and may mimic many developmental
effects of DES (208). Persistent endocrino-
logical and immunological toxic effects of
various perinatal exposures are well known;
these should be studied systematically with
regard to effects on postnatal carcinogenesis.
Cross-Species Comparability
Can these principles from animal studies be
extrapolated to humans? This would be most
convincing for those observed in more than
one animal species. Some of the factors that
we described previously have been evidenced
for only one species. Experiments implicat-
ing the presence of stem cells, levels of
carcinogen-activating enzymes, and the pres-
ence of differentiated tissue have been
reported for more than one species. Evidence
Table 17. Livertumors aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mouse/B6C3 GD 17, 3 months, Xray, 0.5-7 Gy X ray: all groups X ray: 3 months (227)
or 19 months Neutron, 0.09-2.14 Gy Neutrons: GD 17, 3 months Neutrons: GD 17
Mouse/B6WHT GD 17, PN 0 or X ray, GD 150 or300 R, All groups .300 R PN 0 (228)
5weeks PN 400 R
Mouse/B6C3 GD 17, PN 0-365 y137Cs, 1-5.7 Gy GD 17-PN 35 PN 0, 7 (165)
Mouse/NMRI GD 6-20 lx DMBA, 60 mg/kg GD 6-20 (males) GD 14-20 (191)
Mouse/B6C3 GD 12-20 or PN Benzidine, 150 ppm Males: both groups PN (188)
1-21 diet
GD 12-20 or PN Safrole, 120 mg/kg Males: both groups PN
1-21
Mouse/ICR GD 7, 9,11, 13, Urethane, 0.5 or 1 g/kg GD 11-15 GD 13 (229)
15, or 17
Mouse/ICR GD 7-19 Urethane 1 or 0.2 g/kg GD 11-15; 19 if< 12 hr before birth GD 13 (156)
Mouse/B6C3 GD 7-11, 11-15, Urethane, 0.5 g/kg GD 11-18 GD 14-18 (153)
or 14-18
GD 12, 14, 16, or 18 ENU, 60 mg/kg GD 12-18 GD 17-18 (euthanized at
36weeks)
Mouse/B6C3 or GD 12, 14, 16, or 18 ENU, 60 mg/kg GD 12-18 No significant differences (220
C3B6 (natural death)
Mouse/B6C3 GD 12, 14,16, or 18 ENU, 60 mg/kg All groups PN 1, 15 (188)
or PN 1, 15, or42
Mouse/C3HeB GD 10, 13, or 15 ENU, 10, 25, or 50 GD 10-15 Males: GD 15. Livertumor size (230)
mg/kg greatest after GD 10, and more
microvasculature invasion
Females: GD 13
Mouse/NIH Swiss GD 15, 17, and 19 NNK, GD 100 mg/kg, Males: both groups PN (231,232)
or PN 1, 4, 7, 10, PN 50 mg/kg
and 14
Mouse/NIH Swiss GD 15,17, and 19 NNK, GD 100 mg/kg Males: PN 4 (190)
or PN 4 PN 50 mg/kg Females: no effect
GD 19 or PN 4 NDMA, GD 10 mg/kg Males: PN 4
or PN 50 mg/kg Females: PN 4
Mouse/C3H GD 16 or 19 NDMA, 7.4 mg/kg Males: GD 19 (189)
NDEA, 51 mg/kg Females: GD 16, 19; males: GD 19 No difference
ENU, 47 mg/kg Females: GD 19
Mouse/B6C3 PN 1 or 15 mg/kg NDEA, 1.5, 5, or 10 mg/kg Males: all 1.5 mg/kg: PN 15 (188)
5 or 10 mg/kg: no difference
Mouse/NMRI GD 12, 14, or 16 5-azacytidine, 1 or 2 GD 12-16 (males) No significant differences (210)
mg/mouse GD 12 (2 mg) or 14(1 mg)(females)
Mouse/CD-1 GD 12-18 or PN AZT, GD 12.5 or 25 Females: GD 12-18 and PN 1-8 No significant differences (233)
1-8 mg/mouse or
PN 25, 50, 100, 200
mg/kg
Rat/BDIX GD 15 or 22 NDEA, 70 or 150 GD 22 (187
mg/kg
Hamster/SG GD 8-4, lx ENU, 0.5 mmol/kg GD 11-16: cholangiocarcinomas GD 14-16 (224)
All groups: hemangiosarcomas
Ontogeny of liver: Mouse-GD 8: liver primordia with foregut, diverticulum by day 9; 10: discernible liver with epithelial cords, evidence of hematopoiesis by 10.5; 12: many blood cells; 12-15: rapid
growth (fills half the bodycavity byday 15); 18: still mainlyhematopoietic. Rat-GD 11: hepatic diverticulum is formed; 12: epithelial cords begin to appear; 14: adultconfiguration. Hamster-GD 8.5: two
small liverdiverticula appear, along with a few scattered liver cords and hepatic sinusoids; 9-11: right and left lobes evident, size increases, ducts open into the gut, gall bladder primordium appears; 12:
gall bladder separates from liver, liver increasinglydense, with well-formed capsule.
Abbreviations: AZT, 3'-azido-3'-deoxythymidine; DMBA, 7,12,-dimethylbenz[alanthracene; NDMA, Nnitrosodimethylamine; NNK,4-(methyinitrosamino)-1-(3-pyridyl)-1-butanone; PN, days after birth.
'Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of significant numbers of liver tumors in the adult offspring. Unless otherwise specified, these were hepa-
tocellular tumors. Sensitivity highest indicates the period during which the greatest numbers of liver tumors were initiated. bGD or PN of exposure are indicated; lx indicates that exposure was given
once, on each ofthe indicated days. 'The dose ateach exposure isgiven.
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Table 18. Mammary gland tumors aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mouse/NMRI GD 12, 14, or 16 5-azacytidine, 1 or 2 GD 12, 2 mg/kg: decrease (210)
mg/kg
Mouse/NIH Swiss G 12-18 or PN AZT, GD 12.5 or 25 Both groups PN 1-8 (233)
1-8 mg/mouse
PN 25, 50, 100, 200
mg/kg
Rat/Wistar GD 20, adult X ray, 0-216 Gy All groups GD 20 leastsusceptible (240
virgin, or adult
lactating
Rat/SD GD 0-22 or Tritium in DW, 1-100 Pregnancy exposure only: increased (247)
mother during pCi, 6.6-660 rads mammaryfibroadenomas from two
pregnancy total highest doses
Rat/SD GD 10-13 or 15-18 DES, 0.6 pg/day, then Enhancement of appearance of mammary GD 10-13: earlier appearance (207)
DMBA PN 50-57, tumors caused by DMBA: DES on GD of tumors
10 mg/dose GD 10-13 or 15-18
Ontogeny of the mammary glands: Mouse-GD 13: cup-shaped mammary glands. Rat-GD 11: two thickenings of ectoderm extend from shoulder posteriorly to inguinal region as mammary streaks; 13:
downgrowths into the underlying mesenchyme; 15: twelve primary sprouts offuture mammaryglands.
Abbreviations: AZT,3'-azido-3'-deoxythymidine; DW, drinking water; DMBA, 7,12,-dimethylbenz[a]anthracene; PN, days after birth.
&Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of significant numbers of mammary tumors ofthe types indicated in the adultoffspring. Sensitivity highest
indicates the period during which the greatest numbers ofmammarytumors were initiated. bGD or PN ofexposure are indicated. cThe dose at each exposure isgiven.
Table 19. Soft-tissue neoplasms aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mice/B6C3 GD 17, PN 0-365, 1x y-Ray, 137Cs, 3.8 Gy Osteosarcoma: GD 17-PN 100 PN 35 (165)
Mice/BALB/c GD 14 or adult a-Particles, 141Am, 100, 500, 1500 Bq/g(GD) Osteosarcoma: both stages Fetus (243)
or45-213 Bq/g (PN)
Mice/NMRI GD 12, 14, or 16 5-Azac tidine, 1 or 2 mg/kg Sarcoma: GD 12-16 GD 16 (210)
Dog/beagle GD 8, 28, or 55 or PN 2 y-Ray,601Co, 16 or 83cGy Hemangiosarcoma: GD 8, 55 GD 8 (245)
PN, days after birth.
"Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of significant numbers of soft-tissue neoplasms of the types indicated in the adult offspring. Sensitivity
highest indicates the period during which the greatest numbers of soft-tissue neoplasms were initiated. bGD or PN of exposure are indicated. lx indicates a single exposure on the days indicated. cThe
dose ateach exposure isgiven.
Table 20. Thyroid tumors aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mice/CBA GD 18 or PN 96 1311, 2,400-4,700 rad/thyroid (GD) or GD; adenomas - (254)
8,500-9,500 rad/thyroid (PN);
+ 180 rad X-ray to some
Hamster/SG GD 8-14, lx ENU, 0.2 or 0.5 mmol/kg Follicular cell tumors: GD 9-14 GD 12-14 (224)
Dog/beagle GD 8, 28, or 55 or y-Ray, 60Co, 16 or 83 cGy Adenocarcinoma: PN 70 (245)
PN 2, 70, or365
Ontogeny ofthe thyroid gland: Mouse-GD 8.5: thyroid primordium; 10: ducts form; 11: distinct organ; 12-13: becomes solid, lobularorgan; 17: vascular, numerous follicles, colloid. Hamster-GD 8: thy-
roid diverticulum formed at level of second arch; 9.5: thyroid solid, stalk to floor of mouth; 9-11: bilobed, narrow isthmus at level of larynx; 13: glandular with solid epithelial cords and follicle primordia
interspersed with vascularized mesenchyme.
PN, daysafter birth.
&Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of significant numbers ofthyroid tumors of the types indicated in the adult offspring. Sensitivity highest
indicates the period during which the greatest numbers of thyroid tumors were initiated. bGD or PN of exposure are indicated. lx indicates a single exposure on the days indicated. SThe dose at each
exposure is given.
Table 21. Uterine tumors aftertransplacental or neonatal exposures in animals.
Sensitivitya
Species/strain Exposure periodb Agent/dosec Range Highest Reference
Mice/B6WHT GD 12 or 16-18 lx X ray, 200 R Leiomyosarcoma: decrease, GD 12 (150)
Mice/NMRI GD 5-20, lx DMBA, 60 mg/kg Benign: GD 6-20 Benign: GD 20 (191)
Malignant: GD 14-20 Malignant: GD 17
Mice/CD-1 GD 16 or 17 DES, 1 mg/kg Both groups: adenocarcinoma, polyp, No significant difference (252)
leiomyoma of uterus, adenocarcinoma of cervix
Mice/CD-1 GD 9-16 or PN 1-5 DES, GD 0.1 mg/kg Both groups; cervical and uterine (255,256)
PN 1 pg/dose/day leiomyoma/sarcoma, stromal cell sarcoma, PN
adenocarcinoma
Ontogeny of the uterus: Mouse-GD 13.5: Wolffian ducts merge into urogenital sinus; 16: Muellerian ducts differentiate into uterus and uterine tubes; 17: vaginal anlage formed; 19: caudal growth of
vaginal anlage to level below pubic symphysis.
Abbreviations: DMBA, 7,12-dimethylbenz[a]anthracene; PN, days after birth.
"Sensitivity range indicates the ontogenetic period during which exposure led to the appearance of significant numbers of uterine tumors of the types indicated in the adult offspring. Sensitivity highest
indicates the period during which the greatest numbers of uterine tumors were initiated. bGD or PN of exposure are indicated. lx indicates a single exposure on the days indicated. cThe dose at each
exposure is given.
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for the induction of renal nephroblastomas
from mice, hamsters, rats, rabbits, and opos-
sums is in reasonable concurrence that renal
stem cells must be present for this to happen.
A role for fetal carcinogen metabolism has
been directly demonstrated only for lung and
liver in mice, but strong correlative evidence
is available for kidney in rat and upper respi-
ratory tract in hamsters. The apparent need
for the presence ofdifferentiated tissue for a
neoplasm to be initiated has been seen in five
species but with a different target tissue in
each case. It is reasonable to believe that these
factors are likely to be operative in the
human, as well as others such as numbers of
cells at risk, rates ofcell division, and low
capacity ofthe newborn for chemical detoxi-
fication. However, because ofthe high degree
of species specificity in the target tissues
affected, it is impossible to predict which
tissue maybe most vulnerable in humans.
The animal model most relevant to the
human is the nonhuman primate, where
structure ofthe placenta, length ofgestation,
and maturity ofthe fetus at birth resemble
the human condition much more closely than
is the case for rodents. In patas monkeys,
transplacental ENU caused more tumors than
the same dose given to juvenile monkeys,
confirming the quantitatively higher sensitiv-
ity of the fetuses seen for this chemical in
rodents (209). Tumor yield was similar for
treatment throughout gestation and for more
limited treatment during the first two-thirds
ofgestation, and few tumors resulted when
treatment was not started until the beginning
ofthe second trimester. These results sug-
gested that sensitivity was highest during the
first trimester. Neoplasms included relatively
frequent vascular tumors and others ofsoft-
tissue origin. There were also a few tumors
comparable to human childhood cancers,
including nephroblastoma, astrocytoma,
glioma, oligodendroglioma, and leukemia,
confirming the sensitivity ofthe primate fetus
to chemical initiation of these neoplasms.
Embryonal pulmonary blastomas were seen
after transplacental exposure ofrhesus but not
patas monkeys, indicating species differences
among primates.
AnimalModels ofHuman Childhood
Cancers
Ofthe various animal tumors described here,
only the nephroblastomas in rats, rabbits,
oppossums, and monkeys; osteosarcomas in
mice; and lymphomas/leukemias in the mouse
and dog have some direct relevance to com-
mon human childhood cancers. In addition,
cancers ofthe mammary gland and testis may
occur in youngpeople; these have been studied
in relation to perinatal exposures in rats and
mice. Nephroblastomas are a common out-
come in rats, oppossums, and rabbits after the
exposure ofwell-developed kidneys that still
retained a substantial proportion ofstem cells.
In all ofthese species (and in the nonhuman
primate and in humans), nephroblastomas are
apparently metanephric tumors resulting from
a neoplastic deviation ofthe normal ontogeny
ofthe metanephric blastema. This conclusion
is supported by ultrastructural studies and by
occasional findings ofglomeruloid structures
within Wilms' tumors. In the human embryo,
the metanephros is present from the fifth
through the seventh week ofgestation. This
suggests a narrowwindowofsusceptibility ifin
fact some Wilms' tumors are caused by
transplacental exposures.
More limited animal data for osteosar-
coma, which results from radiation, suggest a
broad window ofsensitivity that is greatest in
immature individuals. For lymphomas and
leukemias, findings have been complex.
Myeloid leukemias have been reported only
after postnatal radiation exposure. Lymphomas
and leukemias have been increased after peri-
natal exposure in some studies, with the time
ofhighest sensitivity possiblydependingon the
oncogenic agent. This time was late in gesta-
tion or after birth for ENU, y-radiation, ure-
thane, and X rays but early in gestation for
DMBA. Treatments with nucleoside analogues
led to decreases in hematopoietic neoplasms.
In the experiment ofSchmahl et al. (210),
5-azacytidine caused either an increase or a
decrease in these cancers, depending on the
exact dose and GD oftreatment. These find-
ings point to the possibility ofperinatal win-
dows ofexposure sensitivity to the induction
oflymphomas and leukemias in humans but
fail to give morespecific useful information.
Gaps in Knowledge
Humans
Although animal models have shown that
cancer risk can be increased after exposure to
certain potentially hazardous agents-precon-
ceptionally, in utero, and perinatally-in
humans, much ofthe evidence is equivocal.
This is partly because findings from studies
that have investigated the etiology ofcancer in
relation to prenatal/early life exposures are
often based on small numbers ofcases because
both cancer in young people and many ofthe
potentially hazardous exposures studied are
rare. Figures 3 and 4 compare the statistical
power of cohort studies (disease onset in
exposed individuals compared to disease onset
in unexposed individuals) and case-control
studies (exposures in individuals with the dis-
ease compared to exposures in individuals
without the disease) to detect differences,
should they exist. Figures 3 and 4 show the
number ofsubjects required to give an 80%
chance ofdetecting increased risks at different
exposure levels for typical study designs.
Exposure levels below a general population
level of0.1% are not uncommon in epidemi-
ological studies [paternal occupational expo-
sure to ionizing radiation at work, for
example, would fall into this category (Tables
3 and 4)]. For a rare exposure such as this, to
have an 80% chance ofdetecting a trebling in
risk, disease rates in two cohorts ofequal size
ofapproximately 15,000 subjects would have
to be monitored over time (Figure 3) or past
exposures in approximately 600 cases and
1,200 controls would have to be compared
(Figure 4). Unfortunately, studies as large as
these are rarely conducted and many results
are based on insufficient data.
Most epidemiological studies that have
investigated the etiology ofcancer in young
people have had a case-control design.
Although valid diagnostic information on the
malignancy in question is generally collected,
good quality information on the exposure(s) is
not always available. This is a particular prob-
lem for studies investigating potential etiologi-
cal factors relating to lifestyle-such as diet
and smoking-where data are often self-
reported. When information about exposure
is only obtained for those who participate in a
study, response/recall bias can be exacerbated
by participation bias, which is introduced
when those who respond to a study differ
from those who do not. Because participation
rates are often lower among controls than
among cases, the potential for producing false
negative and false positive findings in
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case-control studies relying on self-reported
exposure information isproblematic.
An additional difficulty in human studies
is that even when exposure data are good,
pinpointing times ofexposure and quantify-
ing dose is rarely straightforward. For exam-
ple, pesticide exposure ofmothers at work
could affect their germ cells, their fetuses, or
their children after birth. In some cases, expo-
sure may have occurred in only one time
period (such as neonatal administration of
vitamin Kor immunization), but for others it
may be impossible to determine the relevant
exposure period (such as maternal smoking).
Individual exposures and the timing ofexpo-
sure cannot always be readily isolated one
from another and observed associations with
one factor may simply reflect associations
with others.
Because epidemiological studies are not
conducted in laboratories, specific questions
about critical time windows in relation to
cancer are not easily answered. This is true
for exposures at all stages oflife, not just pre-
natally and in childhood. With respect to
specific exposures, the situation is much as it
has been for the past 20 years. For the pre-
conceptional period, no exposures are
accepted as definitively associated with pre-
conceptional carcinogenesis. For the in utero
period, only ionizing radiation and DES are
agreed, and even for these, there is still
debate about timing and dose. However,
although no responsible exposure has been
identified, the molecular evidence of Ford
et al. (15,16) linking genetic changes initi-
ated in utero to subsequent leukemia devel-
opment has given added impetus to research
in this area. For perinatal/postnatal exposures
the situation is perhaps less bleak, particu-
larly for those exposures that are only rele-
vant postnatally. With respect to critical time
windows ofexposure, the etiological role of
infectious disease in cancer development is
one of the most active areas of current
research (9,121). Developments in this area,
like those described by Ford et al. (15,16),
require collaboration between epidemiolo-
gists and laboratory-based scientists. Indeed,
the use ofmolecular techniques in epidemi-
ology has increased markedly over the last
few years; perhaps it is through collabora-
tions such as these that questions about the
importance ofexposure dose and timing in
cancer etiology will finally be resolved.
Animal Models
Notable gaps in the rodent data are oftwo
types: mechanistic information about the rea-
sons for observed periods ofhigh sensitivity
and tests ofboth risk situations and concepts
arising from the human data. In the first cate-
gory, there are presently more gaps than firmly
woven stories. None ofthe likely susceptibility
factors have been investigated thoroughly
enough for the information to be used with
assurance in the human context. For some of
the factors, this couldeasily bedone bythe use
ofseveral carcinogenic agents and species and
with carefully planned investigations. For oth-
ers, such as DNA repair, more basic informa-
tion is needed. Putative involvement of
particular enzymes or cell-control molecules
could be tested with current technology for
selective gene inactivation and targeted overex-
pression bytransgenes. Forexample, onecould
test whether transplacental carcinogenesis by
certain nitrosamines in mice is dependent on
activation by cytochrome P4502E1 by using
the already available mice knocked-out in this
gene. Differential gene expression techniques
could be used to search for those genes whose
increase or decrease in expression corresponds
tochanges insensitivityto tumor initiation.
With regard to specific cross-referencing
to human studies, much more work could be
done on risk factors ofspecial concern. For
example, preconceptional carcinogenicity of
radiation has been studied with only a few
animal models, andwith ahighlyvariable out-
come, apparently depending on the dose and
type ofradiation and the species and strain of
test animal. This issue could be systematically
investigated. Paternal tobacco smoking has
been implicated in several studies, but few of
the carcinogens present in tobacco smoke have
been tested as preconceptional carcinogens,
and none have been specifically tested in
males. Furthermore, available data from ani-
mal models hint at a novel mechanism in
play. When eventually uncovered, this knowl-
edge ofmechanism could help in understand-
ing human risk from paternal radiation
exposure, tobacco smoking, etc. Recently sus-
pected human risk factors such as vitamin K
and topoisomerase II inhibitors have not been
tested in perinatal animal models. Although
neonatal rodents are more susceptible to infec-
tions than adults, including infection byonco-
genic viruses, they have not yet been used to
model the cancer-risk role proposed for
human infant exposure to microbes.
There is increasing knowledge ofthe mol-
ecular and genetic changes in human child-
hood cancers. The meaningfulness of the
comparable animal model neoplasm as a risk
indicator would be indicated bysimilarities or
dissimilarities in molecular etiology. For
example, several tumor-susceptibility genes or
chromosomal areas have been identified in
human Wilms' tumors ofthe kidney; these
could be examined in rat and rabbit nephrob-
lastoma. Similarly, K-rasoncogene mutations
have been found in rat nephroblastomas but
apparently have not been tested for Wilms'
tumors.
It should be emphasized that at present it
seems highly unlikely that anyofthisworkwill
ever be done. Only a handful oflaboratories
worldwide are working on perinatal carcino-
genesis in animal models. Ifregulatoryagencies
desire these data, they will have to demand
(and pay for) them. Large, long, expensive
studies will be needed. Industry might be
required to do certain bioassays but cannot be
expected to gather much ofthe bioassay or any
ofthemechanistic information.
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